

# Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)

Systematic Review



Ludwig Boltzmann Institut  
Health Technology Assessment

Decision Support Document No. 104  
ISSN online: 1998-0469



# Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)

Systematic Review



Ludwig Boltzmann Institut  
Health Technology Assessment

Vienna, March 2017

### **Project Team**

Project leader: Dr. med Katharina Hawlik, MSc

Authors: MA Michal Stanak, AKC  
Dr. med Katharina Hawlik, MSc

### **Project Support**

Systematic literature search: Tarquin Mittermayr, BA

External Review: Priv.-Doz. Dr. Tudor Birsan  
Specialist general and digestive surgeon,  
Fellow of the European Board of Surgery/Division Coloproctology

Internal Review: Priv.-Doz. Dr. phil. Claudia Wild

### **Correspondence**

MA Michal Stanak, AKC, [michal.stanak@hta.lbg.ac.at](mailto:michal.stanak@hta.lbg.ac.at)

### **This report should be referenced as follows:**

Stanak M, Hawlik K. Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD).

Decision Support Document No. 104; 2017. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

### **Conflict of interest**

All authors and the reviewers involved in the production of this report have declared they have no conflicts of interest in relation to the technology assessed according to the Uniform Requirements of Manuscripts Statement of Medical Journal Editors ([www.icmje.org](http://www.icmje.org)).

The external reviewer declares no conflict of interests.

### **Disclaimer**

The external reviewers did not co-author the scientific report and do not necessarily all agree with its content. Only the LBI-HTA is responsible for errors or omissions that could persist. The final version and the policy recommendations are under the full responsibility of the LBI-HTA.

The HTA Core Model<sup>®</sup>, developed within EUnetHTA ([www.eunetha.eu](http://www.eunetha.eu)), has been utilised when producing the contents and/or structure of this work. The following version of the Model was used: Core Model<sup>®</sup> 3.0. Use of the HTA Core Model does not guarantee the accuracy, completeness, quality or usefulness of any information or service produced or provided by using the Model.

**Commissioned by the Austrian Ministry of Health**, this report systematically assessed the intervention described herein as decision support for the inclusion in the catalogue of benefits.

## **CONTENT INFORMATION**

### **Publisher:**

Ludwig Boltzmann Gesellschaft GmbH  
Nußdorferstr. 64, 6 Stock, A-1090 Wien  
<http://hta.lbg.ac.at/page/imprint>

### **Responsible for content:**

Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)  
Garnisonsgasse 7/20, A-1090 Vienna  
<http://hta.lbg.ac.at/>

Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize the research results of the Ludwig Boltzmann Institute of Health Technology Assessments.

Decision support documents of the LBI-HTA are only available to the public via the Internet at <http://eprints.hta.lbg.ac.at/>,

Decision Support Document No.: 104

ISSN-online: 1998-0469

© 2017 LBI-HTA – All rights reserved

# Content

Summary.....	5
Zusammenfassung .....	8
1 Scope .....	13
1.1 PICO question .....	13
1.2 Inclusion criteria .....	13
2 Methods .....	15
2.1 Research questions .....	15
2.2 Sources.....	16
2.3 Systematic literature search.....	16
2.4 Flow chart of study selection .....	17
2.5 Analysis .....	18
2.6 Synthesis.....	18
3 Description and technical characteristics of technology .....	19
4 Health Problem and Current Use.....	23
5 Clinical effectiveness .....	29
5.1 Outcomes.....	29
5.2 Included studies.....	29
5.3 Results .....	30
6 Safety.....	31
6.1 Outcomes.....	31
6.2 Included Studies .....	31
6.3 Results .....	32
7 Quality of evidence .....	35
8 Discussion .....	37
9 Recommendation .....	41
10 References.....	43
Appendix.....	45
Evidence tables of individual studies included for clinical effectiveness and safety .....	45
Risk of bias tables .....	49
Applicability table .....	50
List of ongoing trials.....	51
Literature search strategies .....	52
Search strategy for Cochrane.....	52
Search strategy for CRD .....	52
Search strategy for Embase.....	53
Search strategy for Medline.....	53
Search strategy for PubMed .....	53

**List of Figures**

Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) .....17  
 Figure 3-1: The EST device parts and the EST electrode position and IPG implant location [5, 7] .....19  
 Figure 4-1: Algorithmic approach to medical treatment of GERD [17] .....26  
 Figure 4-2: Decision tree in anti-reflux surgical therapy, adapted [14].....27

**List of tables**

Table 1-1: Inclusion criteria .....13  
 Table 7-1: Evidence profile: efficacy and safety of the EST in GERD patients .....36  
 Table 9-1: Evidence based recommendations .....41  
 Table A-1: EST: Results from observational studies .....45  
 Table A-2: Risk of bias – study level .....49  
 Table A-3: Summary table characterising the applicability of a body of studies.....50  
 Table A-4: List of ongoing trials of the EST .....51

**List of abbreviations**

AEs .....adverse events	IPG .....implantable pulse generator
ACG.....American College of Gastroenterology	IQR.....inter-quartile range
AWMF .....Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften	LP .....Laparoscopic Fundoplication
AVNRT.....Atrioventricular Nodal Re-entrant Tachycardia	LBI-HTA ...Ludwig Boltzmann Institute for Health Technology Assessment
BE.....Barrett’s Esophagus	MRI .....Magnetic Resonance Imaging
BMI .....body mass index	MSAD .....Magnetic Sphincter Augmentation Device
CE Mark ...Conformité Européene mark	min .....minutes
CT.....controlled trial	mos .....months
DMC .....Data Monitoring Committee	NA .....not available
DRG .....Diagnosis-Related Group	NERD .....Non-Erosive Reflux Disease
EST.....Electric Stimulation Therapy	pts .....patients
ESTD .....Electric Stimulation Therapy Device	pre-op. ....pre-operative
GERD .....Gastroesophageal Reflux Disease	PPI.....Proton Pump Inhibitor
GRADE ....Grading of Recommendations Assessment, Development and Evaluation	RCT .....randomized controlled trial
HRQL .....Health-related quality of life	SAE.....serious adverse event
H2RA .....H2-receptor antagonist	SD .....standard deviation
	TIF .....Trans-oral Incisionless Fundoplication
	yrs .....year

# Summary

## Introduction

### Health Problem

Gastroesophageal reflux disease (GERD) is defined according to the Montreal consensus as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications, whereby troublesome means that they adversely affect an individual's well-being [1].

From a surgical perspective, GERD is the failure of the antireflux barrier, caused by a defective LES, a gastric emptying disorder, or failed esophageal peristalsis. The abnormalities result in a spectrum of disease ranging from symptoms only, such as heartburn, to esophageal tissue damage with or without subsequent complications including malignancy or airway disease [1].

### Description of Technology

Electric stimulation therapy (EST) represents a novel method for the surgical treatment of GERD. The EST comprises of three components: a bipolar stimulation lead with two stitch electrodes, an implantable pulse generator, and an external programmer [2]. The EST implant procedure is performed using standard laparoscopic techniques where a pair of electrodes is placed in the anterior part of the lower esophagus and sutured in place [3]. The wires are then connected to a stimulator placed in the subcutaneous pocket in left upper quadrant of the abdominal wall [3]. The goal of the intervention is to reinforce the weak lower esophageal sphincter (LES) by delivering mild electrical signals to the LES throughout the day. The stimulation aims to restore normal function of the LES, preventing reflux from the stomach entering the esophagus.

## Methods

The EUnetHTA Core Model for Rapid Relative Effectiveness was the main source for selecting relevant assessment elements. We conducted a systematic literature search (without restriction on publication date) in bibliographic databases (Medline via Ovid, Embase, the Cochrane Library, PubMed, database of the Centre for Reviews and Dissemination) to answer the research questions in the domains effectiveness and safety. Two researcher selected the relevant documents (in English) independently. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used for qualitatively summarising the results for the domain: „Safety”.

### Domain effectiveness

For analysing clinical effectiveness, prospective controlled studies were included. The crucial outcome to derive a recommendation was GERD HRQL score.

### Domain safety

For analysing safety, prospective controlled and uncontrolled studies were included. The crucial outcomes to derive a recommendation were: device erosion and trocar perforation of the small bowel during laparoscopy. Other relevant outcomes were post-operative bloating/belching, post-operative dysphagia, pain/discomfort, and nausea/vomiting.

**Gastroesophageal reflux disease**

**failure of the antireflux barrier, the lower esophageal sphincter (LES)**

**EST, a novel surgical treatment option for GERD**

**laparoscopic intervention**

**electrical stimulation to reinforce the weak LES**

**based on EUnetHTA Core Model, systematic literature search in 5 databases, GRADE**

**inclusion criteria for effectiveness**

**inclusion criteria for safety**

<p><b>2 single arm prospective case series, 70 patients</b></p>	<p><b>Results</b></p> <p><b>Available evidence</b></p> <p>A total of two single-arm prospective case series and one prospective registry were eligible for inclusion in the current report. Overall, safety was evaluated in the total of 70 patients.</p>
<p><b>no study fulfilled the study inclusion criteria</b></p>	<p><b>Clinical effectiveness</b></p> <p>No study fulfilled the study inclusion criteria for assessing clinical effectiveness of the EST.</p>
<p><b>no direct comparison for EST and standard practice</b></p>	<p><b>Safety</b></p> <p>In the absence of data from controlled studies, no comparisons can be made between the EST and the surgical alternative treatment, laparoscopic fundoplication (LF). Device and procedure related complications were reported in one study with 6 months follow-up [4]. Lead erosion through esophagus occurred in 2.4% out of 42 patients and was followed by the device explantation. One procedure related complication, trocar perforation of the small bowel during laparoscopy, occurred also in 2.4% out of 42 patients. No other device or procedure related complications were reported.</p>
<p><b>lead erosion in 2.4% patients (out of 42 patients)</b></p>	<p>A number of short-term post-operative harms occurred. The following adverse events occurred in one study [4] (in % of patients): constipation 2.4%, epigastric pain 2.4%, hiccups 4.8%, inability to vomit 4.8%, and fever 2.4%. The following adverse events occurred in both case series [4, 5] (in % of patients): post-operative bloating/belching in 7.1% and 0%, post-operative dysphagia in 9.5% and 0%, nausea/vomiting in 7.1% and 12%, and pain/discomfort in 45.2% and 20%. No new adverse events occurred in the registry study.</p>
<p><b>postoperative AEs: constipation, pain, hiccups, inability to vomit, fever, post operative bloating and dysphagia</b></p>	<p><b>Upcoming evidence</b></p> <p>There is an ongoing study in the US and Europe that is a multicenter, randomized, double-blind, sham-controlled clinical trial (NCT02749071).</p>
<p><b>1 ongoing multicentre RCT</b></p>	<p><b>Reimbursement</b></p> <p>Currently, the use of EST for the treatment of GERD is not reimbursed by the Austrian health care system.</p>
<p><b>currently not reimbursed</b></p>	<p><b>Discussion</b></p> <p>Overall, the quality of evidence was very low and the overall risk of bias was considered moderate. Internal validity of the trials conducted was undermined by the use of the concomitant therapy of Proton Pump Inhibitors (PPIs) in all trials.</p>
<p><b>quality evidence needed, high risk of bias</b></p>	<p>Major advantages of the EST known to date are that it is less invasive and reversible, its implantation is associated with a short learning curve for the surgeon, it presumably allows a faster return to normal diet, and it requires a shorter hospital stay compared to LF.</p>
<p><b>advantages of the EST are lesser invasiveness, easier intervention, shorter hospital stay</b></p>	<p>The target population of the EST, however, seems to be less severe patients not indicated for LF and hence, a sham RCT is needed to confirm efficacy of the EST. Crucial outcome measures should include the device's ability to reduce the likelihood of developing GERD complications, like esophageal cancer, and the long-term safety considerations, like the durability of the device and device removals.</p>
<p><b>target population are GERD patients not indicated for LF</b></p>	



## Conclusion

The current evidence is not sufficient to prove that the EST is at least equally effective and as safe as the comparator LF. There are no available comparative data on the two procedures or placebo controlled data on the EST and hence, no conclusions are made about the device effectiveness. Concerning safety, only device related complications were reported based upon data from prospective case series. These suggest a relatively safe profile of the EST that, however, needs to be confirmed by a high quality RCT, which will potentially influence the effect estimate considerably. Re-evaluation is recommended in 2022, as December 2021 is the estimated ongoing study (NCT02749071) completion date.

The inclusion in the catalogue of benefits is currently not recommended.

**current evidence does not prove effectiveness of the EST and safety needs to be confirmed**

**reevaluation in 2022**

**inclusion not recommended**

# Zusammenfassung

## Einleitung

### Indikation und therapeutisches Ziel

<b>gastroösophageale Refluxkrankheit (GERD): Prävalenz 15 %</b>	Die gastroösophageale Refluxkrankheit (GERD) ist eine häufige Erkrankung in den Industrieländern der westlichen Welt mit einer Prävalenz von bis zu 15 % und einer zunehmenden Inzidenz. Aufgrund ihrer zunehmenden Häufigkeit beansprucht die Behandlung von GERD wachsende Ressourcen. Zu den beeinflussenden Faktoren für die Entstehung von GERD zählen falsche Ernährung (Fettleibigkeit, erhöhter Fettkonsum, Essen unmittelbar vor dem zu Bett gehen) und ein passiver Lebensstil (Bewegungsmangel).
<b>Ernährung &amp; Lebensstil</b>	
<b>Symptome: Sodbrennen, Aufstoßen, Magenschmerzen Schweregrade: mild, moderat, schwer</b>	Typische Symptome von GERD sind: Sodbrennen, Aufstoßen, Magenschmerzen. Zu den atypischen Symptomen zählen: chronischer Husten, Heiserkeit, Dysphagie, Schmerzen in der Brust, chronische Aspiration, Bronchitis, Sinusitis. Auf Basis der Häufigkeit und Schwere der Reflux-Symptome, wird von milder, moderater und schwerer GERD gesprochen, jedoch ohne explizite Definition über die Dauer der Erkrankung und die Art der Messung der verschiedenen Stadien.
<b>progrediente Erkrankung</b>	Der natürliche Verlauf der Erkrankung ist unklar. Traditionell wird die Krankheit als Spektrum beginnend mit nicht-erosivem Reflux (NERD), der sich zu GERD (erosive Ösophagitis, Stenose, Barrett-Ösophagus) entwickelt, beschrieben. Das Management von GERD wird durch die Schwere der Symptome bestimmt. Die Leitlinien der „American College of Gastroenterology“ (ACG) und der „Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften“ (AWMF) schlagen ein schrittweises Vorgehen vor
<b>ACG &amp; AWMF: schrittweises Vorgehen bei Interventionen</b>	
<b>Gewichtsverlust,</b>	<ul style="list-style-type: none"><li>✦ Als erste Interventionen werden Veränderungen in der Ernährung und im Lebensstil vorgeschlagen,</li><li>✦ Gewichtsverlust für GERD-PatientInnen, die übergewichtig sind,</li></ul>
<b>Vermeidung von Mahlzeiten vor Zubettgehen, H<sub>2</sub>RA Therapie, 8 Wochen PPI, PPI Erhaltungstherapie,</b>	<ul style="list-style-type: none"><li>✦ Oberkörperhochlage und Vermeidung von Mahlzeiten 2-3 Stunden vor dem Zubettgehen für PatientInnen mit nächtlicher GERD,</li><li>✦ bei mild bis moderater Schwere der Symptome: ein H<sub>2</sub>-Rezeptor-Antagonist (H<sub>2</sub>RA) Therapie,</li><li>✦ wenn eine H<sub>2</sub>RA Therapie nicht ausreichend ist, und der/die PatientIn moderate bis schwere Symptome hat: Initiierung einer 8-wöchigen Therapie mit Protonenpumpeninhibitoren (PPI),</li><li>✦ bei anhaltenden GERD Symptomen ist eine PPI-Erhaltungstherapie (mit niedriger Dosierung) indiziert.</li></ul>
<b>Operation: Therapie 2. Wahl</b>	<ul style="list-style-type: none"><li>✦ Eine Operationsindikation ist gegeben, wenn zusätzlich zur langfristigen Behandlungsbedürftigkeit folgende Indikationskriterien erfüllt sind: intolerable Reflux-induzierte Restbeschwerden oder eine Unverträglichkeit gegenüber der PPI-Therapie besteht.</li></ul>

## Beschreibung der Technologie

Die elektrische Stimulationstherapie (EST) stellt eine neuartige Methode zur chirurgischen Behandlung von GERD dar. Die EST besteht aus drei Komponenten: einer bipolaren Stimulationsleitung mit zwei Maschenelektroden, einem implantierbaren Impulsgenerator und einem externen Programmierer [2]. Die EST-Implantat-Prozedur wird unter Verwendung von Standard-laparoskopischen Techniken durchgeführt, bei denen ein Paar Elektroden in den vorderen Teil des unteren Ösophagus platziert und an der Stelle vernäht wird [3]. Die Drähte werden dann mit einem Stimulator verbunden, der in der subkutanen Tasche im linken oberen Quadranten der Bauchwand platziert ist [3]. Das Ziel der Intervention ist es, den schwachen unteren Ösophagussphinkter (LES) durch die Bereitstellung von milden elektrischen Signalen an die LES den ganzen Tag zu verstärken. Die Stimulation zielt darauf ab, die normale Funktion der LES, die Vermeidung von Reflux aus dem Magen in die Speiseröhre, wiederherzustellen.

## Methoden

Die Beantwortung der Forschungsfragen bezüglich Wirksamkeit und Sicherheit erfolgte anhand einer systematischen Literatursuche in folgenden Datenbanken:

- ✿ Medline via Ovid,
- ✿ Embase,
- ✿ the Cochrane Library,
- ✿ CRD (DARE, NHS-EED, HTA)

Zusätzlich wurde eine Handsuche durchgeführt und der Hersteller kontaktiert. Die Studienauswahl erfolgte unabhängig durch beide AutorInnen (MS, KH). Der Erstautor (MS) extrahierte die Studiendaten und die Zweitautorin (KH) kontrollierte die Daten.

Die Daten der für die Entscheidung herangezogenen Endpunkte wurden aus den einzelnen Studien zusammengefasst und nach GRADE (Grading of Recommendations Assessment, Development and Evaluation) bewertet. Zusätzlich wurde das Bias-Risiko der Studien von beiden AutorInnen unabhängig voneinander bewertet.

## Klinische Wirksamkeit

Zur Bewertung der Wirksamkeit des LINX® Reflux Management Systems wurde der GERD HRQL score als *entscheidend* für eine Empfehlung erachtet. Weitere *wichtige* Endpunkte waren Sodbrennen, tägliches Aufstoßen, extra-ösophageale Symptome, Absetzen oder Reduktion von PPI-Medikamenten.

Der GERD HRQL score misst die Veränderungen in typischen GERD-Symptomen nach einer chirurgischen oder medizinischen Behandlung. Der GERD HRQL score enthält Fragen zu Sodbrennen, Schwierigkeiten beim Schlucken, Blähungen und zur Medikamenteneinnahme. Die bestmögliche Punktzahl ist 0 (asymptomatisch), die schlechteste Punktzahl ist 50.

**EST neue Technologie für chirurgische GERD Therapie**

**laparoskopischer Eingriff**

**elektrische Stimulation um normale LES Funktion herzustellen**

**Suche nach Publikationen in mehreren Datenbanken**

**Kontakt mit Hersteller**

**4-Augenprinzip bei Studienauswahl, Extraktion der Daten, Kontrolle**

**GRADE & Risk of Bias Beurteilung**

**entscheidender Endpunkt zur Beurteilung der Wirksamkeit: GERD HRQL**

**GERD HRQL score misst GERD-Symptome:**

**0-50 Punkte**

<b>entscheidende Endpunkte zur Beurteilung der Sicherheit: Prozedur- und Produkt-induzierte Komplikationen</b>	<b>Sicherheit</b> <p>Zur Bewertung der Sicherheit wurden die folgenden <i>entscheidenden</i> Endpunkte für eine Empfehlung herangezogen:</p> <ul style="list-style-type: none"><li>✿ Erosion des Produktes</li><li>✿ Trokarperforation im Zuge des laparoskopischen Eingriffes</li></ul> <p>Weitere <i>wichtige</i> Endpunkte waren:</p> <ul style="list-style-type: none"><li>✿ Post-operative übermäßige Blähungen und Aufstoßen</li><li>✿ Übelkeit und Erbrechen</li><li>✿ Schmerzen, Unwohlsein</li></ul>
<b>2 prospektive, einarmige Fallserien, 1 Fallregister 70 Patienten</b>	<b>Ergebnisse</b> <b>Verfügbare Evidenz</b> <p>Insgesamt konnten zwei einarmige prospektive Fallserien und ein Fallregister identifiziert werden. Da keine der Studien die Einschlusskriterien für die Bewertung der Wirksamkeit erfüllte, konnten die Studien mit einer Gesamtzahl von 70 PatientInnen nur zur Bewertung der Sicherheit herangezogen werden.</p>
<b>keine Studien zur Beurteilung der Wirksamkeit</b>	<b>Klinische Wirksamkeit</b> <p>Keine Studie erfüllte die Einschlusskriterien zur Beurteilung der klinischen Wirksamkeit.</p>
<b>Erosion und Trokarperforation in 2.4 % der PatientInnen</b>	<b>Sicherheit</b> <p>Aufgrund fehlender kontrollierter Studien konnten keine Vergleiche zwischen EST und der derzeitigen Standardtherapie laparoskopische Fundoplikatio (LF) durchgeführt werden. Produkt- und prozessbedingte Komplikationen wurden in einer Studie mit einem Follow-up von 6 Monaten berichtet. Erosionen im Bereich der Speiseröhre traten in 2,4 % der 42 PatientInnen auf, woraufhin die Geräte explantiert wurden. Eine Trokarperforation der Dünndarmwand im Zuge der Laparoskopie trat in 2,4 % der 42 PatientInnen ein. Es wurden keine weiteren prozess- oder produktbezogenen Komplikationen beschrieben.</p>
<b>Postoperative AE: Blutungen, Verstopfung, Oberbauchschmerzen, Schluckauf, gestörter Würgerreflex, Fieber</b>	<p>Des Weiteren wurde eine Reihe kurzfristiger postoperativer Schäden berichtet (Anzahl der PatientInnen in Prozent der jeweiligen Studie): Verstopfung 2,4 %, epigastrische Schmerzen 2,4 %, Schluckauf 4,8 %, Erbrechen und Fieber 2,4 %, postoperative Blähungen/Aufstoßen in 7,1 % und 0 %, postoperative Dysphagie in 9,5 % und 0 %, Übelkeit/Erbrechen in 7,1 % und 12 % und Schmerzen/Unwohlsein in 45,2 % und 20 %. Die Patientenregisterstudie berichtete keine zusätzlichen unerwünschten Ereignisse.</p>
<b>1 laufendes RCT</b>	<b>Laufende Studien</b> <p>Derzeit gibt es eine laufende randomisierte, multizentrische doppel-blinde Studie in den USA und Europa, die die Intervention im Vergleich zu einer Scheinbehandlung untersucht (NCT02749071).</p>
<b>derzeit nicht erstattet</b>	<b>Kostenerstattung</b> <p>EST wird in Österreich zurzeit nicht erstattet.</p>

## Diskussion

Insgesamt war die Qualität der Evidenz, aufgrund der Fehlenden Daten aus kontrollierten Studien, der Heterogenität der Ergebnisse, und der kleinen Stichprobengröße, sehr gering. Das Gesamtrisiko für Verzerrungen wurde als moderat eingestuft. Die hochspezifische PatientInnengruppe der Studien ist nicht repräsentativ für GERD-PatientInnen, die eine chirurgische Therapie benötigen.

Die wesentlichen Vorteile der EST wären die Reversibilität und die niedrigere Invasivität des Verfahrens, die vermutlich eine schnellere Rückkehr zur normalen Diät erlaubt. Die Implantation des Produktes ist mit einer kurzen Lernkurve für ChirurgInnen assoziiert. Des Weiteren weist die Intervention einen kürzeren Krankenhausaufenthalt im Vergleich zur LF auf.

Im Unterschied zur LF, die nur bei schweren GERD Fällen indiziert ist, scheint allerdings die Zielpopulation für EST auch moderatere GERD PatientInnen einzubeziehen, für die LF und chirurgische Verfahren primär nicht indiziert wären. Daher ist zur Beurteilung der Wirksamkeit ein Schein-RCT essentiell, in der das Gerät implantiert, bei der Kontrollgruppe aber vorerst nicht aktiviert wird.

Entscheidende Endpunkte für zukünftige Studien und die Bewertung der Wirksamkeit und Sicherheit sollten zusätzlich Langzeitfolgen beinhalten – wie zum Beispiel die Verminderung der Zahl an Speiseröhrenkrebskrankungen und die Haltbarkeit des Produktes.

## Empfehlung

Die vorhandene Evidenz lässt keine Rückschlüsse zu, ob EST mindestens gleich wirksam und genauso sicher ist wie der Komparator LF.

Es gibt keine kontrollierten Studien, um die Wirksamkeit von EST im Vergleich zu LF oder einer Scheinbehandlung zu bewerten. Des Weiteren konnten entscheidende Sicherheitsendpunkte nur auf Basis von Daten aus prospektiven Fallserien bewertet werden. Diese deuten darauf hin, dass EST ein relativ sicheres Verfahren ist. Jedoch ist eine Bestätigung dieser Ergebnisse durch ein RCT notwendig, da dies die Empfehlung stark beeinflussen könnte.

Eine neuerliche Evaluierung wird für 2022 empfohlen, da im Dezember 2021 das laufende Schein-RCT fertig gestellt werden wird (NCT02749071).

Auf Basis der derzeit verfügbaren Evidenz wird die Aufnahme von EST in den Leistungskatalog nicht empfohlen.

**Qualität der Evidenz  
gering, Bias Risiko  
moderat**

**Vorteile der EST wären  
geringe Invasivität,  
einfache Intervention**

**Zielpopulation:  
GERD PatientInnen  
ohne LF Indikation**

**Evidenz nicht  
ausreichend um  
Wirksamkeit und  
Sicherheit zu bewerten**

**Re-Evaluierung 2022**

**Aufnahme nicht  
empfohlen**



# 1 Scope

## 1.1 PICO question

Is Electric Stimulation Therapy (EST) in comparison to the standard surgical treatments (Nissen fundoplication, partial or Toupet fundoplication) in patients with chronic gastroesophageal reflux disease (GERD) more effective or equally effective concerning improvement in GERD-Health-related quality of life (HRQL), and safer regarding the post-operative side effects and serious adverse events?

**PIKO-Frage**

## 1.2 Inclusion criteria

Inclusion criteria for relevant studies are summarized in Table 1-1.

**Einschlusskriterien  
für relevante Studien**

*Table 1-1: Inclusion criteria*

<b>Population</b>	Adult patients with chronic (>6 months) GERD, diagnosis based on 24 pH monitoring, LES end-expiratory pressure of 5-15 mmHg, peristaltic contractions seen in $\geq 50\%$ of swallows with a contraction amplitude of $\geq 30$ mmHg during baseline esophageal manometry, typical symptoms of GERD (heartburn, or regurgitation), esophagitis grade C or lower (LA classification), and at least partial response to therapeutic medication with PPIs as 2 <sup>nd</sup> line treatment. MeSH-term: Electric Stimulation Therapy, Electric Stimulation
<b>Intervention</b>	Electric stimulation therapy device (EST) inserted through laparoscopic surgery Product name: EndoStim <sup>®</sup> LES Stimulator MeSH-term: Gastroesophageal reflux, Gastroesophageal reflux
<b>Control</b>	<ul style="list-style-type: none"> <li>✳ Sham treatment (placebo)</li> <li>✳ Standard surgical treatment of GERD: Nissen fundoplication, partial or Toupet fundoplication</li> <li>✳ PPI therapy</li> </ul>
<b>Outcomes</b>	
<b>Efficacy</b>	Clinical endpoint: <ul style="list-style-type: none"> <li>✳ GERD-Health-related quality of life (HRQoL)</li> </ul> Intermediate outcomes: <ul style="list-style-type: none"> <li>✳ Heartburn</li> <li>✳ Regurgitation</li> <li>✳ Extra-esophageal symptoms</li> <li>✳ Discontinuation of anti-reflux medication (PPIs)</li> <li>✳ Improvement in LES pressure</li> </ul>
<b>Safety</b>	Adverse events (AEs), serious adverse events (SAEs): <ul style="list-style-type: none"> <li>✳ Dysphagia</li> <li>✳ Excessive bloating</li> <li>✳ Inability to belch or vomit</li> <li>✳ Operation related complications</li> <li>✳ Device related complications (migration, erosion, malfunction, removal, removal)</li> <li>✳ Re-hospitalisation</li> <li>✳ Re-operation</li> </ul>

<b>Study design</b>	
Efficacy	Randomised controlled trials (RCTs) Prospective non-randomised controlled trials (CTs)
Safety	Randomised controlled trials Prospective non-randomised controlled trials Prospective single-arm studies, registries



## 2 Methods

### 2.1 Research questions

Description of the technology	
Element ID	Research question
B0001	What is electric stimulation therapy (EST) and the alternative standard treatment option(s)?
B0002	What is the claimed benefit of the EST in relation to the alternative standard treatment option?
B0003	What is the phase of development and implementation of the EST and the alternative standard treatment option?
B0004	Who administers the EST and fundoplication and in what context and level of care are they provided?
B0008	What kind of special premises are needed to use the EST and the alternative standard treatment options?
B0009	What supplies are needed to use the EST and the alternative standard treatment option?
A0020	For which indications has the electric stimulation therapy device (ESTD) received marketing authorisation or CE marking?
A0021	What is the reimbursement status of the EST?

Health problem and Current Use	
Element ID	Research question
A0001	For which health conditions and for what purposes is the EST used?
A0002	What is the disease or health condition in the scope of this assessment?
A0003	What are the known risk factors for gastroesophageal reflux disease (GERD)?
A0004	What is the natural course of GERD?
A0005	What is the burden of GERD for the patients with the disease or health condition?
A0006	What are the consequences of GERD for the society?
A0024	How is GERD currently diagnosed according to published guidelines and in practice?
A0025	How is GERD currently managed according to published guidelines and in practice?
A0007	What is the target population in this assessment?
A0023	How many people belong to the target population?
A0011	What is the expected annual utilisation of the EST?

Clinical Effectiveness	
Element ID	Research question
D0001	What is the expected beneficial effect of the EST on mortality?
D0005	How does the EST affect heartburn, regurgitation, and extraesophageal symptoms?
D0006	How does the EST affect the continuation with PPI therapy?
D0011	What is the effect of the EST on dysphagia and bloating?
D0016	How does the EST affect activities of daily living?
D0013	What is the effect of the EST on disease-specific quality of life?
D0017	Were patients satisfied with the EST?

Safety	
Element ID	Research question
C0008	How safe is the EST in comparison to LF?
C0002	Are there harms related to dosage or frequency of applying the technology?
C0004	How does the frequency or severity of harms change over time or in different settings?
C0005	What are the susceptible patient groups that are more likely to be harmed through the use of the technology?
C0007	Are EST and LF associated with user-dependent harms?
B0010	What kind of data/records and/or registry is needed to monitor the use of EST and LF?

## 2.2 Sources

### Description of the technology

- Quellen**
- ✿ Handsearch in the POP, MDS, Syngerus, Ohtanen and CRD databases for Health Technology Assessments
  - ✿ Background publications identified in database search: see Section 2.3
  - ✿ Documentation provided by the manufacturers

### Health problem and Current Use

- ✿ Handsearch in the POP, MDS, Syngerus, Ohtanen and CRD databases for Health Technology Assessments
- ✿ Background publications identified in database search: see Section 2.3
- ✿ Documentation provided by the manufacturers
- ✿ Erdös J, Stanak M. Magnetic Sphincter Augmentation Device (MSAD) in patients with gastroesophageal reflux disease (GERD). Decision Support Document No. 101; 2016. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

## 2.3 Systematic literature search

### systematische Literatursuche in 5 Datenbanken

The systematic literature search was conducted from January 2<sup>nd</sup> to February 3<sup>rd</sup> in the following databases:

- ✿ Medline via Ovid
- ✿ Embase
- ✿ The Cochrane Library
- ✿ CRD (DARE, NHS-EED, HTA)
- ✿ PubMed

At the time of the systematic literature search, no limitations to the study design were applied. In addition, handsearch of literature (web-search) was performed. After deduplication, overall 345 citations were included. The specific search strategy employed can be found in the Appendix.

EndoStim Inc., the manufacturer of EndoStim® LES Stimulator, submitted 28 publications of which 0 new citations were identified.

**insgesamt  
367 Publikationen  
identifiziert**

By hand-search, an additional 22 citations were found, resulting in overall 367 hits.

## 2.4 Flow chart of study selection

Overall, 367 hits were identified. The references were screened by two independent researchers (MS, KH) and in case of disagreement, a third researcher was involved to solve the differences. The selection process is displayed in Figure 2-1.

**Literaturauswahl**




Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram)

## 2.5 Analysis

### **Systematische Datenextraktion**

The data retrieved from the selected studies were systematically extracted into a data-extraction-table (see Appendix Table A-1). No further data processing (e.g. indirect comparison) was applied. Two independent researchers (MS, KH) systematically assessed the quality of evidence (see Table 7-1) and the risk of bias using the checklists presented in the Appendix Table A-2).

## 2.6 Synthesis

### **Zusammenfassung der Ergebnisse mit GRADE**

Based on the data-extraction-table (see Appendix Table A-1), data on each selected outcome category were synthesised across studies according to GRADE (Grading of Recommendations Assessment, Development and Evaluation) [6]. The research questions were answered in plain text format with reference to GRADE evidence tables (see Table 7-1).

### 3 Description and technical characteristics of technology

#### Features of the technology and comparators

##### Boo01 – What is electric stimulation therapy (EST) and the alternative standard treatment option?

The EST comprises of three components: a bipolar stimulation lead with two stitch electrodes, an implantable pulse generator (IPG), and an external programmer (see Figure 3-1) [2]. The stimulation lead is 45 cm long and has sterile bipolar, stitch platinum-iridium electrodes at the end. The IPG is made of hermetically sealed titanium case construction (size 65x48x12 mm and weight 49 g), it is connected to the stimulation leads, and permanently implanted in a subcutaneous pocket in the left upper quadrant of the abdomen [2]. The IPG contains a medical grade lithium battery, microelectronics, communication coils, and an accelerometer for sensing patient posture [2]. The IPG is programmed by an external programmer via laptop PC software [2].

The EST implant procedure is performed using standard laparoscopic techniques. A pair of electrodes are placed in the anterior part of the lower esophagus 1 cm apart and sutured in place [3]. Endoscopic visualization of the gastroesophageal junction is used to ensure that the wires do not enter the lumen [7]. The wires are then connected to a stimulator placed in the subcutaneous pocket in left upper quadrant of the abdominal wall [3]. It is recommended that the patient wears an elastic compression bandage over the pulse generator implantation site for 10-14 days in order to reduce the chances of seroma formation [8].

The stimulator may be switched on or off remotely, and the polarity of its current and pattern of stimulation can be modulated. Patients are not supposed to be aware of the stimulators activity [3]. The electrical stimulation is initiated 12 hours after the implant procedure. The current is applied intermittently through the day in specified time periods and can be personalized. Electrical stimulation is delivered using a 215-1s pulse at 20 Hz and 3-8 mA in 30 min sessions, 6-12 time per day [5, 8].

**EST besteht aus 3 Komponenten: Stimulationsdraht mit 2 Elektroden, implantierbarer Pulsgenerator, externer Programmierer**

**Implantation erfolgt mittels Standard laparoskopischem Eingriff**

**Durch die externe Programmierung kann der Stimulator an und ab geschaltet werden, sowie die Polarität und Stromstärke adaptiert werden**




Figure 3-1: The EST device parts and the EST electrode position and IPG implant location [5, 7]

**Marketed products**

**derzeit ist EndoStim®  
das einzige zugelassene  
Produkt**

**2 Generationen des  
Produktes sind am  
Markt**

**Hauptunterschied zw  
EndoStim I® und  
EndoStim II®:  
Kompatibilität mit  
MRT scannern**

**Chirurgische  
Standardmethode:  
Fundoplikatio**

**Nissen Fundoplikatio:  
vollständige Manschette  
wird um Ösophagus  
gelegt**

**partielle Fundoplikatio:  
270 Grad Manschette**

**keine standardisierte  
Operationstechnik**

**4-6 Wochen  
Rekonvaleszenz,  
zunächst nur flüssige  
Nahrung**

There is currently only one EST on the market, the EndoStim® LES Stimulator developed by EndoStim Inc. [3]. The EndoStim® device has two generations. The first-generation device, EndoStim I®, has a larger battery lasting approximately 10 years. The second-generation device, EndoStim II®, is 25% thinner and has 40% less volume [9]. EndoStim II® has a battery lasting approximately 7 years. Correspondence with EndoStim Inc. indicated that the therapy delivered as well as the lead and electrodes used are identical in both devices.

The main difference between EndoStim I® and EndoStim II® lies in their compatibility with Magnetic Resonance Imaging (MRI) scans. EndoStim II® announced the CE Mark approval for full body scans using 3.0 Tesla MRI machines in October 2015. Imaging of the head and extremities may also continue to be performed using both 1.5-Tesla and 3-Tesla systems [10]. In the United States, EndoStim II® seeks approval by the FDA and is currently allowed for investigational use only [11].

**Current standard procedure**

The current standard surgical treatment of GERD means wrapping the fundus of the stomach around the esophagus to create a new valve at the level of the esophagogastric junction, a technique called fundoplication. Options include Nissen fundoplication and partial or Toupet fundoplication.

✦ Nissen fundoplication is currently the gold-standard and the most common surgical treatment with around 2000 procedures carried out in Austria per annum. It was first performed in 1955 by an open technique, but it is now typically carried out laparoscopically. High-quality evidence suggests the superiority of laparoscopy to open surgery concerning early outcomes (hospital stay, fewer complications) with no significant differences in late outcomes; although the reoperation rate is higher in the short-term [12, 13]. It is a complete or total wrap that encompasses 360° of the esophagus in a posterior fashion.

✦ Partial fundoplication has two versions, but only one is recommended for the treatment of GERD, i.e Toupet fundoplication (posterior wrap), which covers roughly 270° of the posterior esophagus [13]. Partial fundoplication is associated with less post-operative dysphagia, fewer reoperations, and its effectiveness is similar to total fundoplication in terms of controlling GERD symptoms up to five years after surgery. However, there are concerns about the long-term effectiveness of partial fundoplication [12].

Laparoscopic fundoplication (LF) is technically difficult and it may be performed differently by different surgeons, which has a high impact on patient outcomes. Although the most common is a loose (floppy) Nissen fundic wrap including a posterior hiatal hernia repair, the surgical technique has yet to be standardized to improve patient outcomes.

The recovery time can be 4-6 weeks and patients may need to be on a pure liquid diet for one week after surgery before they can gradually start a soft food diet [14].

### *Hiatal hernia and its repair*

The esophagus passes through an opening in the diaphragm (the oesophageal hiatus) before it joins the stomach. If the stomach slips through the diaphragm into the chest, a condition called hiatal hernia develops. Hiatal hernia might be a cause of GERD [15], therefore, depending on its size, it is often repaired (posterior crural repair) at the time of anti-reflux surgery at the surgeons' discretion to ensure the success of the anti-reflux surgery. A sliding hernia of up to 3 cm can be effectively repaired by approximating the crura with interrupted stiches [16].

Hiatal hernia repair can be done in both interventions. Fundoplication allows for a concurrent hiatal hernia repair. LF is recommended for patients with hiatal hernia >2 cm or patients with their gastroesophageal junction in the chest [14].

#### **Boo02 – What is the claimed benefit of the EST in relation to the alternative standard treatment option?**

The claimed major benefits of the EST compared to LF are its lesser invasiveness and reversibility [17]. The laparoscopic insertion of the device requires little dissection and few steps, therefore, the operative time is shorter. The operation technique is less difficult, hence, its reproducibility is higher and the learning curve for the surgeon is also expected to be shorter [12, 18]. The EST procedure claims to be associated with fewer side-effects and a shorter hospital length of stay [4].

#### **Boo03 – What is the phase of development and implementation of the EST and the alternative standard treatment option?**

The EST was first implanted in a clinical setting in Chile in a single-centre, prospective, open-label case series (NCT01578642) in 25 patients [8]. Correspondence with the manufacturer suggests that device was first implanted in October 2010 and since then, 564 devices have been implanted. The EST is a novel technology that is in its emerging phase and hence, it is not part of the standard practice. Current clinical trials are investigating the use of the EST in other subgroups of GERD patients (after laparoscopic sleeve gastrectomy) that have been so far excluded from the use of the device [19]. Correspondence with EndoStim Inc. indicated that there is an ongoing study in the US and Europe that is a multicenter, randomized, double-blind, sham-controlled clinical trial (NCT02749071), including results of the previously interrupted European RCT (NCT02514616). This trial is supposed to serve as the basis for evaluation of efficacy of the EST for FDA approval. New versions of the device with substantial improvements are not expected in the near future.

Fundoplication was first performed in 1955 and has become the standard surgical anti-reflux treatment. It has several modifications, of which two (Nissen and Toupet) are most commonly used and accepted in the clinical practice.

**Hiatushernie Reparatur in Antireflux Chirurgie**

**Potentielle Vorteile: Weniger invasiver und kürzerer Eingriff, Reversibilität, einfachere Prozedur für Chirurgen**

**Neue Technologie**

**Laufendes multizentrisches RCT soll Daten zur Wirksamkeit vorweisen**

**verbesserte Versionen des Produktes sind nicht in Planung**

**chirurgische Standardmethode: Fundoplikatio**

Administration, Investments, personnel and tools required to use the technology and the comparator(s)

**B0004 – Who administers the EST and fundoplication and in what context and level of care are they provided?**

**B0008 – What kind of special premises are needed to use the EST and the alternative standard treatment options?**

**B0009 – What supplies are needed to use the EST and the alternative standard treatment option?**

**Fundoplikatio sollte nur in GERD-Zentren mit hoher PatientInnen-Frequenz durchgeführt werden**

Both the EST and LF are performed under general anaesthesia by a foregut surgeon. The guidelines suggest that LF is to be done in high-volume centres by experienced foregut surgeons. Surgeons with little experience should have expert supervision during their early experience with the procedure to minimize morbidity and improve patient outcomes [12].

The premises, the operation team, and the supplies are similar; the only difference is the device itself.

Regulatory & reimbursement status

**Indikation: chronische GERD PatientInnen mit anhaltenden Symptomen > 6 Monaten**

**A0020 – For which indications has the electric stimulation therapy device (ESTD) received marketing authorisation or CE marking?**

The EndoStim<sup>®</sup> LES Stimulation System is intended for the treatment of patients with chronic GERD with symptom duration of 6 months or longer [9].

**A0021 – What is the reimbursement status of the EST?**

**bislang nicht erstattet**

To our knowledge, the EST is only reimbursed in Germany. The costs associated with the EST operation include the price of the device (8.240 €), and the operation procedure (facilities, staff, anaesthesia, hospital stay). The information about the former was provided by the manufacturer.

**Kosten: 8.240 € Materialkosten**

**Im Vergleich zu Fundoplikatio: Materialkosten, Erstausbildung von ChirurgInnen sind ein Zusatz, führt aber zu kürzeren OP-Zeiten**

In comparison to fundoplication, the material costs (device) and the initial training of surgical staff to undertake the implantation procedure are additional to the costs of the LF operation procedure; although the EST procedure might cost slightly less due to its shorter operation time. The EndoStim<sup>®</sup> device is reimbursed in the German DRG-System up to the amount of 12.508,49€. In Austria, there are currently one centre where the EST is available.



## 4 Health Problem and Current Use

Overview of the disease or health condition

**A0001 – For which health conditions and for what purposes is the EST used?**

**A0002 – What is the disease or health condition in the scope of this assessment?**

The EST is used in patients with GERD, which is defined according to the Montreal consensus as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Symptoms are considered troublesome if they adversely affect an individual's well-being [1]. The EST is a second-line treatment for GERD patients in whom PPI medication failed to achieve complete symptom alleviation, symptoms recur despite initial successful medication, and for those who refuse to take life-long medication or suffer from side-effects of PPI therapy. The main aim of the EST is alleviation of symptoms by strengthening the weak LES, the anatomical cause of GERD. The EST is not curative, but long-term (life-long) use is essential to maintain the treatment effect.

From the surgical perspective, GERD is the failure of the anti-reflux barrier, which, when functioning improperly, allows abnormal reflux of gastric contents into the esophagus. It is a mechanical disorder caused by a defective LES, a gastric emptying disorder, or failed esophageal peristalsis. The abnormalities result in a spectrum of disease ranging from symptoms only, such as heartburn, to esophageal tissue damage with or without subsequent complications, including malignancy or airway disease [1].

Reflux can be categorized based on symptoms or based on its nature.

Symptom based approach differentiates between typical and atypical symptoms:

- ✧ Typical symptoms: heartburn, regurgitation, epigastric pain.
- ✧ Atypical symptoms: chronic cough, hoarseness, globus, dysphagia, chest pain, chronic aspiration, bronchitis, sinusitis.

Based on its nature, GERD can be acid or non-acid.

- ✧ Acid reflux with a  $\text{pH} < 4.0$
- ✧ Non-acid reflux with a  $\text{pH} > 4.0$

Non-acid reflux is poorly understood yet [14].

A generally accepted definition on the severity of GERD is lacking. Based on the frequency and severity of the experienced reflux symptoms, expressions used in the literature range from mild, through moderate, to severe GERD. However, there is no explicit definition clarifying the duration and measurement of the symptoms.

**A0003 – What are the known risk factors for gastroesophageal reflux disease (GERD)?**

There are anatomical and patient factors that can contribute to the development of reflux. The anatomical factors are related to the LES, the diaphragmatic crura, and the phrenoesophageal ligament. The patient factors include diet and lifestyle, as well as obesity. Eating refluxogenic foods, overeating,

**GERD:**  
**Reflux aus dem Magen in die Speiseröhre**

**EST:**  
**2.Linie Behandlung nach Therapieversagen für chronische GERD-PatientInnen**

**Symptome:**  
**Sodbrennen, Aufstoßen, Magenschmerzen**

**typische und atypische Symptome**

**acid oder non-acid Refluxkrankheit**

**Schweregrade:**  
**mild, moderat, schwer**

**anatomische Faktoren, Ernährung & Lebensstil**

eating immediately before going to bed, increased fat consumption in the diet, and expanding proportion of obese individuals are significant risk factors for GERD. In obese patients, the intra-gastric pressure and the frequency of transient LES relaxations is chronically increased, which is thought to be the cause of GERD [14, 20].

#### **A0004 – What is the natural course of GERD?**

The natural history of the disease has not been well clarified yet. Currently, two concepts exist:

ungeklärter  
natürliche Verlauf  
Spektrum beginnend  
mit nicht-erosivem  
Reflux (NERD), der sich  
zu GERD entwickelt  
  
GERD Komplikationen:  
erosiver Ösophagitis,  
Stenose,  
Barrett-Ösophagus  
  
neues Konzept:  
3 individuelle  
Beschwerden (NERD,  
erosive Ösophagitis,  
Barrett-Ösophagus)

✧ The traditional concept sees the disease as a spectrum that starts with non-erosive reflux disease (NERD) and might progress to complicated GERD (erosive esophagitis, stricture, Barrett’s esophagus (BE)). This concept focuses on esophageal mucosal injury as the most significant clinical outcome in GERD. Patients with severe esophagitis are at high risk of developing a stricture and long-standing reflux symptoms are a major risk for developing BE. Patients with BE have an increased risk of esophageal adenocarcinoma with a 40 times greater incidence than in the general population [20].

✧ The new concept considers GERD as a categorical disease with three distinct entities: NERD, erosive esophagitis, and BE. According to this concept, these are different disorders and the movement among them is limited. This concept focuses on mechanisms leading to symptom generation rather than mucosal injury. Some studies suggest that GERD is a chronic disease that is not progressive. However, other studies confirm that progression of NERD to erosive esophagitis is possible in 10% of GERD patients [20].

Both of these concepts assume that NERD might progress to GERD, it is debated though to what extent.

Effects of the disease or health condition  
on the individual and society

#### **A0005 – What is the burden of GERD for the patients with the disease or health condition?**

Lebensqualität  
  
Lebensstil, Ernährung  
lebenslange Medikation

Quality of life is impacted through the experience of GERD symptoms such as heartburn, extra-esophageal manifestations (pulmonary or ear, nose, throat), or non-cardiac chest pain [21].

Patients often complain about sleep disturbance. Their diet is also affected as the foremost treatment suggested is life-style and diet modification. Presumably, they also need to take life-long medication that may have serious side effects, be badly tolerated, alter the absorption of minerals and vitamins, have metabolic effects on bone density, pharmacokinetics or pharmacodynamics and related drug interactions and effects, or enhance the infection risk and hypersensitivity response with consequent organ damage [17].

#### **A0006 – What are the consequences of GERD for the society?**

zunehmende  
Häufigkeit, wachsende  
Ressourcennutzung

Due to its increasing incidence (approximately 5 per 1,000 person-years in the Western world [22]), GERD is leading to a growing utilisation of health resources (medical consultations, emergency room visits, hospitalization, and medication). Not only the doctor visits and diagnosis carry high financial expenses, but also the medication and the operation costs need to be considered in the long run [23].

The burden of disease on the individual affecting work productivity results in substantial societal burden and employer costs [17].

Current clinical management of the disease or health condition

#### A0024 – How is GERD currently diagnosed according to published guidelines and in practice?

According to the American College of Gastroenterology (ACG) and the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Guidelines [24, 25], the recommendations for the diagnosis of GERD (along with the level of evidence and the level of strength of the recommendation) are the following:

- ✳ A presumptive diagnosis of GERD can be established in the setting of **typical symptoms of heartburn and regurgitation**. Empirical medical therapy with PPIs is recommended in this setting (strong recommendation, moderate level of evidence).
- ✳ Patients with **non-cardiac chest pain** suspected due to GERD should have **diagnostic evaluation** before the institution of therapy (conditional recommendation, moderate level of evidence). A cardiac cause should be excluded in patients with chest pain before the commencement of a gastrointestinal evaluation (strong recommendation, low level of evidence).
- ✳ **Upper endoscopy** is recommended in the presence of alarm symptoms and for screening of patients at high risk for complications (strong recommendation, moderate level of evidence).
- ✳ **Ambulatory esophageal reflux monitoring** is indicated before the considerations of endoscopic or surgical therapy in patients with NERD, as part of the evaluation of those patients who are refractory to PPI therapy and in situations when the diagnosis of GERD is in question (strong recommendation, low level evidence). Ambulatory reflux monitoring is the only test that can assess reflux symptom association (strong recommendation, low level of evidence).

**ACG & AWMF:  
Richtlinien zur Diagnose  
der Refluxkrankheit**

#### A0025 – How is GERD currently managed according to published guidelines and in practice?

The management of GERD is aligned with the severity of symptoms. The ACG and AWMF Guidelines [24, 25] suggest a stepwise approach that starts with lifestyle modifications including:

- ✳ **Weight loss** for GERD patients who are overweight or have had recent weight gain (conditional recommendation, moderate level of evidence).
- ✳ **Head of bed elevation** and **avoidance of meals 2-3 hours before bedtime** for patients with nocturnal GERD (conditional recommendation, low level of evidence).

From *mild to moderate* severity symptoms, first a

- ✳ **H2-receptor antagonist (H2RA) therapy** is recommended. This can be used as a maintenance option in patients without erosive disease if patients experience heartburn relief (conditional recommendation, moderate level of evidence).

**ACG & AWMF:  
schrittweises Vorgehen  
bei Interventionen**

**Gewichtsverlust  
Vermeidung von  
Mahlzeiten vor  
Zubettgehen**

**H2RA Therapie**

If H2RA therapy is not sufficient and the patient has *moderate to severe* symptoms:

- 8 Wochen PPI**
  - ✦ An **8-week course of PPIs** is the therapy of choice for symptom relief and healing of erosive esophagitis. There are no major differences in efficacy between the different PPIs (strong recommendation, high level of evidence).
- PPI mit niedriger Dosierung indiziert**
  - ✦ **PPI therapy** should be initiated at **once a day dosing** before the first meal of the day (strong recommendation, moderate level of evidence).
  - ✦ For patients with **partial response to once daily PPI therapy**, tailored therapy with **adjustment of dose timing and/or twice daily dosing** should be considered (strong recommendation, low level of evidence). Switching to a different PPI may provide additional symptom relief (conditional recommendation, low level evidence).
- PPI-Erhaltungstherapie**
  - ✦ **Maintenance of PPI therapy** should be administered for GERD patients who continue to have symptoms after PPI is discontinued and in patients with complications including erosive esophagitis and BE (strong recommendation, moderate level of evidence). For patients who require long-term PPI therapy, it should be administered in the lowest effective dose, including on demand or intermittent therapy (conditional recommendation, low level of evidence).
  - ✦ **Non-responders to PPIs** should be referred for **evaluation** (conditional recommendation, low level of evidence).

Recommendations number 1-2 can only prevent approximately 20% of patients from a relapse. The relapse rate after discontinuation of the medication accounts for 90% [26].

**refraktär GERD:  
kein standardisierter  
Management-  
Algorithmus**

For patients with refractory GERD, there is no standardized management algorithm. The primary goal of the treatment is symptom reduction and eventual elimination [21].

The management of GERD is displayed in the following figure.




Figure 4-1: Algorithmic approach to medical treatment of GERD [17]

Life-style modifications and medical treatment are the first-line therapy options. Surgical management is the second-line treatment. Before considering surgery, objective documentation of the gastroesophageal reflux is mandatory. Surgical therapy should be considered in patients who:

- ✿ have failed medical management (inadequate symptom control, severe regurgitation not controlled with acid suppression, or medication side effects);
- ✿ opt for surgery despite successful medical management (due to quality of life considerations, lifelong need for medication intake, price of medications, etc.);
- ✿ have complications with GERD (e.g. BE, peptic stricture);
- ✿ have extra-esophageal manifestations (asthma, hoarseness, cough, chest pain, aspiration).

The coexistence of Barrett’s esophagus with gastroesophageal reflux symptoms is considered a clear indication for antireflux surgery. Surgical intervention for asymptomatic BE is, however, more controversial [1, 27].


It is important to note that there is no one best operation for all patients. Factors such as the degree of esophageal shortening, local expertise with laparoscopic techniques, prior operations and esophageal motility disorders, and the size of the hiatal hernia can influence the choice of operation [27].

Choice of surgical procedure is displayed in the following figure:

**Operation:  
Therapie 2.Wahl**

**Indikationsstellung für OP:  
moderate/schwere GERD,  
PPI-Therapieversagen,  
PPI-Nebenwirkungen,  
GERD Komplikationen**

**Entscheidungsbaum in Antireflux Chirurgie**



*TLESR: Transient lower esophageal sphincter relaxation; TIF: trans-oral incisionless fundoplication, LES: lower esophageal sphincter*

Figure 4-2: Decision tree in anti-reflux surgical therapy, adapted [14]

## Target population

### A0007 – What is the target population in this assessment?

The target population in this assessment is adult patients with moderate to severe GERD, who are considered for surgical treatment due to incomplete symptom control despite maximum medication treatment or severe complications associated with PPI therapy.

### A0023 – How many people belong to the target population?

**Prävalenz 15 %  
25-42 % der  
PatientInnen sind  
einmal pro Tag  
PPI-refraktär  
42 % unzufrieden  
mit PPI-Therapie**

The prevalence of GERD is around 15% [1, 24] and the incidence is increasing. It is the most common upper gastrointestinal disease in the Western countries with 10-20% of the population experiencing weekly symptoms [20]. 25-42% of patients are refractory to a once-daily PPI, of which 25% would respond to an increase in PPI dosing to twice daily. However, 42% of GERD patients are dissatisfied with their PPI treatment outcomes [21].

According to data from the Hauptverband, in 2014 in Austria, the Code LM030 (open fundoplication/hiatusplasty) was reimbursed 98 times, the LM040 (laparoscopic fundoplication/hiatusplasty) was refunded 1,723 times.

### A0011 – What is the expected annual utilisation of the EST?

**jährlich  
100 Interventionen**

The expected annual utilisation of EST, according to the Hauptverband, based on the previous years' experience, is 100 interventions per year in Austria.

## 5 Clinical effectiveness

### 5.1 Outcomes

The following outcomes were defined as *crucial* to derive a recommendation:

- ✿ GERD HRQL

Further outcomes considered were:

- ✿ Heartburn
- ✿ Regurgitation
- ✿ Discontinuation with medication (PPIs)
- ✿ Esophagitis

GERD health-related quality of life score:

Since, according to the traditional concept, GERD is a degenerative disease, the ultimate aim of the EST is to stop the process of degeneration by improving the function of the esophageal sphincter and thus improving the quality of life. Hence, GERD health-related quality of life (HRQL) score is considered a relevant primary outcome as the score represents a summation of patient-relevant items. It measures changes in typical GERD symptoms in response to a surgical or medical treatment and so includes questions about heartburn, difficulty with swallowing, bloating, and medication intake. The best possible score is 0 (i.e., asymptomatic in each item) and the worst possible score is 50 (incapacitated in each item). It also reflects on patient satisfaction as it includes a question worded „How satisfied are you with your present condition?“ This item is a numerical score and it is not reflected in the total GERD-HRQL score (21).

**QoL ist wichtigster  
Endpunkt für  
Empfehlung**

**weitere relevante  
Endpunkte:  
Sodbrennen,  
Aufstoßen, Absetzen  
der PPI Medikation,  
Ösophagitis**

**GERD HRQL score misst  
GERD-Symptome**

### 5.2 Included studies

Study characteristics and results of included studies are displayed in Table A-1 and Table A-2 and in the evidence profile in Table 7-1.

No study fulfilled the study inclusion criteria for assessing clinical effectiveness of the EST. RCTs and non-randomised CTs were considered for inclusion, but could not be identified through the systematic literature search (see Figure 2-1).

The systematic literature search (see Figure 2-1) did not identify any comparative trials matching our inclusion criteria for efficacy. The two prospective case series [4, 5] and one prospective registry study [28] are described in the results on safety.

**keine Studie erfüllte  
Einschlusskriterien**

## 5.3 Results

keine Evidenz zu Mortalität und Morbidität	Mortality
	<b>Do001 – What is the expected beneficial effect of the EST on mortality?</b> No evidence was found to answer the research question.
keine Evidenz zu Absetzen der PPI Medikation, Schluckstörungen und Blähungen	Morbidity
	<b>Do005 – How does the EST affect heartburn, regurgitation, and extraesophageal symptoms?</b> No evidence was found to answer the research question.
	<b>Do006 – How does the EST affect the continuation with PPI therapy?</b> No evidence was found to answer the research question.
keine Evidenz zu ADL GERD HRQL Patientenzufriedenheit	Function
	<b>Do011 – What is the effect of the EST on dysphagia and bloating?</b> No evidence was found to answer the research question.
	<b>Do016 – How does the EST affect activities of daily living?</b> No evidence was found to answer the research question.
	Health-related quality of life
	<b>Do012 – What is the effect of the EST on disease-specific quality of life?</b> No evidence was found to answer the research question.
	Patient satisfaction
	<b>Do017 – Were patients satisfied with the EST?</b> No evidence was found to answer the research question.



## 6 Safety

### 6.1 Outcomes

The following outcomes were defined as *crucial* to derive a recommendation:

- ✿ Device erosion
- ✿ Trocar perforation of the small bowel during laparoscopy

Further outcomes considered were:

- ✿ Post-operative bloating/belching
- ✿ Post-operative dysphagia
- ✿ Nausea/vomiting
- ✿ Pain/discomfort

**entscheidende Safety  
Endpunkte:**  
Erosion des Produktes,  
Trokarperforation

**weitere Endpunkte:**  
postoperative  
Schluckstörungen,  
Übelkeit, Erbrechen,  
Schmerz

### 6.2 Included Studies

The study inclusion criteria for assessing safety differed from the ones for assessing clinical effectiveness. In addition to RCTs and non-randomised CTs, prospective studies without a control group (interventional single arm studies, case series, and registry studies) were considered for the assessment of safety. The systematic literature search (see Figure 2-1) identified two prospective case series [4, 5] and one prospective registry study [28], which matched our inclusion criteria. Study characteristics and results of included studies are shown in Table A-1 and Table A-2, and in the evidence profile in Table 7-1.

**2 prospektive Fallserien,  
1 prospektives  
Fallregister**

#### *Study characteristics*

Overall, out of the total of 70 patients included in the studies, baseline characteristics data were reported on 67 patients, of which 29 were women and 38 were men. The registry study included 18 patients, but reported on 15 patients, of which 7 were women and 8 were men [28]. All three studies were sponsored by the manufacturer EndoStim Inc. Countries of recruitment were Colombia, India, Netherlands, Mexico, New Zealand, United Kingdom [4], and Chile [4, 5, 28]. Study recruitment times were October 2010 until January 2011 in the single center case series [5], and April 2011 until July 2014 in the multi-centre case series [4], as stated by the manufacturer. Clinical follow-up time ranged from 6 months to 3 years. Loss to follow-up ranged from 6.8-19.2%. Model versions of the technology (generations of EndoStim<sup>®</sup>) were not reported in any of the studies. The multi-centre case series study included 44 patients [4], the single-centre case series included 26 [5], and the registry 18 patients [5, 28]. The registry study was a continuation of the single centre case series [5, 28].

**insg. 70 PatientInnen  
alle Studien finanziert  
durch den Hersteller**

**Follow- up:  
6 Monate bis 3 Jahre**

#### *Patient characteristics*

The mean age of patients varied between 49.6 [4]-56.1 [28]. The mean BMI ranged from 27.2-27.7 [4, 5]. There were differences in the presence of a hiatal hernia in the multi-centre [4] and the single centre study [5]: 39-88% of patients had no hiatal hernia, 8-22% of patients had hiatal hernia <2 cm, and

**Durchschnittl. Alter:  
zw 50 und 60 Jahren  
Median BMI: 27**

**gemeinsame  
Einschlusskriterien:  
vorangelegene GERD  
Symptomatik,  
PPI Medikation,  
Ösophagitis,  
usw.**

4-39% of patients with hiatal hernia >2 cm. The mean number of years that patients used PPIs was not stated in one study [4] and, in the remaining two studies, it was 5.6 [5] and 5.0 [28]. The mean number of years that patients experienced GERD symptoms prior to the study was not stated in one study [4] and, in the remaining two studies, it was 11 [5] and 12.2 [28].

Patient inclusion and exclusion criteria of the single centre case series and the single centre registry were the same at baseline, however, the inclusion criteria for the patients that continued in the registry were not reported.

The inclusion criteria shared by both case series were: previous reflux symptoms, prior PPI use, esophagitis grade ≤C, diagnosis based on 24-h pH monitoring result, LES end-expiratory pressure of 5–15 mmHg, peristaltic contractions in ≥50% of swallows (respectively in 70% of swallows[5]) with contraction amplitude of ≥30 mmHg oesophageal manometry, and excessive lower esophageal acid exposure as pH <4.0 for ≥5% of the total time [4, 5].

In contrast, the two case series showed also several differences. The age range varied from 21-80 [4] to 21-65 years [5]. Improvement in GERD-HRQL score ≥20 off PPIs and ≥10 on PPIs was an inclusion criterion in the single centre study [5], while in the multi-centre study, the increase of ≥5 on PPIs was sufficient [4]. ASA Physical Status Classification ≤II was an inclusion criterion in the single centre study [5].

**Ausschlusskriterien  
der Studien**

Both case series reported patient exclusion criteria that mainly referred to history of esophageal surgery, multisystem disease, Barrett’s esophagus, any dysplasia, hiatal hernia ≥3 cm, BMI>35, history of diabetes mellitus, gastric malignancy, cardiac arrhythmia, cardiovascular disease, pregnancy, or implanted electro-medical devices [4, 5].

## 6.3 Results

### Patient safety

#### Coo08 – How safe is the EST in comparison to LF?

**keine direkter Vergleich  
zw. EST und LF möglich  
da keine Daten von CTs  
vorhanden**

In the absence of data from controlled studies, no comparisons can be made between the EST and LF. Only device related complications can be considered for the analysis of safety because the effects directly attributable to the device can be analysed without a control group.

**Erosionen in  
2.4 % der PatientInnen**

Device related complications were reported in one study with 6 months follow-up [4]. Lead erosion through esophagus occurred in 2.4% of patients and was followed by the device explantation. One procedure related complication, trocar perforation of the small bowel during laparoscopy, occurred also in 2.4% of patients. No other device related complications were reported.

#### Coo02 – Are there harms related to dosage or frequency of applying the technology?

**korrekte Implantation  
entscheidend**

Safe use of the EST is sensitive to the proper implantation and functioning of the implanted electronic device. Correct delivery of the electrical stimulation, correct lead impedance (which was out of range in 4.8% of patients in one study [4]), and correct IPG implantation (where skin infections at pocket site occurred to 4% of patients [5]) are required.

#### **C0004 – How does the frequency or severity of harms change over time or in different settings**

A number of short term post-operative harms occurred. The following adverse events occurred in one study [4] (in % of patients): constipation 2.4%, epigastric pain 2.4%, hiccups 4.8%, inability to vomit 4.8%, and fever 2.4%. The following adverse events occurred in both case series [4, 5] (in % of patients): post-operative bloating/belching in 7.1% and 0%, post-operative dysphagia in 9.5% and 0%, nausea/vomiting in 7.1% and 12%, and pain/discomfort in 45.2% and 20%. No new adverse events occurred in the registry study.

The only known data to report on the safety profile differences between generations of the EST is the difference between compatibility of the device generations with MRI, where EndoStim® II is approved for full body scans using 3.0 Tesla MRI, while EndoStim® I can only be used for imaging of the head and extremities using 1.5-Tesla [10].

There is no evidence that harms increase or decrease in different organizational settings.

**postoperative AE:  
Blutungen, Verstopfung,  
Oberbauchschmerzen,  
Schluckauf, gestörter  
Würgereflex, Fieber**

#### **C0005 – What are the susceptible patient groups that are more likely to be harmed through the use of the technology?**

Patient groups that are most likely to be harmed through the use of the technology are patients with other comorbidities. Cardiac patients are susceptible to harm as the EST may interact with the patient's heart function or heart devices. Claimed to be unrelated to the EST, a SAE occurred in the multi-centre study where a case of paroxysmal atrioventricular nodal re-entrant tachycardia (AVNRT) occurred several months after the start of the EST [4]. Furthermore, patients that are required to undergo magnet therapy are susceptible to harm as 4% of patients had the EST turned off by magnet therapy for arthritis [5]. Patients with psychological disorders are likely to be harmed as a case of psychotic disturbance/nervous breakdown occurred in 4% of patients in the single centre study [5]. Moreover, patients allergic to metals are susceptible to possible harm caused by the device as well as patients with eating disorders, as the case of weight loss/anorexia occurred in 11.9% of patients in the multi-centre study [4].

**Komorbiditäten  
erhöhen das Risiko für  
AE, insb. Bei Kardialer  
Vorerkrankung**

#### **C0007 – Are the EST and LF associated with user-dependent harms?**

The learning curve for the implantation procedure of the EST is claimed to be short and the esophagogastric junction left unaltered, making the EST reversible [29]. When placing the electrodes, the surgeon needs to avoid perforation of the esophageal lumen [2]. Furthermore, correct set up of the electrical stimulation by the gastroenterologist is crucial to minimize the risk of device malfunctioning.

**kurze Lernkurve,  
reversible Intervention  
Expertise nötig für  
Korrektes Set up,  
CAVE: Perforation**

#### **Investments and tools required**

##### **B0010 – What kind of data/records and/or registry is needed to monitor the use of EST and LF?**

The existing registry study is missing some important information such as the device model type used, electrical set up of the device, reasons for deciding whether specific AEs and SAEs are related, possibly related, or unrelated to the intervention, and reporting on the outcomes of extraesophageal symptoms, hospital discharge, and improvement in esophagitis for all patients.

**Daten zu Type des  
Medizinproduktes,  
set-up und AE,  
SAE fehlen**



## 7 Quality of evidence

The strength of evidence was rated according to GRADE (Grading of Recommendations Assessment, Development and Evaluation) scheme [1] for each endpoint individually. Each study was rated by two independent researchers. In case of disagreement a third researcher was involved to solve the difference. A more detailed list of criteria applied can be found in the recommendations of the GRADE Working Group [1].

**Qualität der Evidenz  
nach GRADE**

GRADE uses four categories to rank the strength of evidence:

- ✧ **High** = We are very confident that the true effect lies close to that of the estimate of the effect;
- ✧ **Moderate** = We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different;
- ✧ **Low** = Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect;
- ✧ **Very low** = Evidence either is unavailable or does not permit a conclusion.

The ranking according to the GRADE scheme for the research question can be found in Table 7-1.

Overall the strength of evidence for the effectiveness and safety of the EST is very low. No evidence was available for the comparison of the EST and LF.

**Stärke der Evidenz  
sehr niedrig**

Table 7-1: Evidence profile: efficacy and safety of the EST in GERD patients

No of studies/patients	Study Design	Estimate of effect	Study limitations	Inconsistency	Indirectness	Other modifying factors	Strength of evidence
<b>Efficacy</b>							
Due to the lack of a controlled group, no data on efficacy can be reported.							
<b>Safety</b>							
<b>Adverse events (AEs)</b>							
<b>Post-operative bloating/belching</b>							
3/67 [4, 5, 28]	Prospective case series + prospective registry	Not reported	-1 <sup>1</sup>	-1 <sup>2</sup>	o	-1 <sup>3</sup>	Very low
<b>Post-operative dysphagia</b>							
3/67 [4, 5, 28]	Prospective case series + prospective registry	Not reported	-1	-1	o	-1	Very low
<b>Nausea/vomiting</b>							
3/67 [4, 5, 28]	Prospective case series + prospective registry	Not reported	-1	-1	o	-1	Very low
<b>Pain/discomfort</b>							
3/67 [4, 5, 28]	Prospective case series + prospective registry	Not reported	-1	-1	o	-1	Very low
<b>Serious adverse events (SAEs)</b>							
<b>Trocar perforation of the small bowel</b>							
1/42 [4]	Prospective case series	Not reported	-1	NA	o	-1	Very low
<b>Device erosion lead through esophagus</b>							
1/42 [4]	Prospective case series	Not reported	-1	NA	o	-1	Very low

**Nomenclature for GRADE table:**

Limitations: 0: no limitations or no serious limitations; -1: serious limitations

Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency

Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty

Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)

<sup>1</sup> Unclear risk of bias due to unclear allocation concealment, no blinding, no control group

<sup>2</sup> Heterogeneous results, no p-value reported

<sup>3</sup> Small sample size

## 8 Discussion

Because the Electric Stimulation Therapy is a new intervention that received the CE Mark in 2012 and currently seeks the FDA approval, there is scarce data on the clinical effectiveness and safety of the device. We could identify three prospective observational studies, two case series [4, 5] and one registry study [28], including the total of 70 patients.

### *Quality of evidence*

Overall, the quality of evidence was very low due to the observational study design, heterogeneity of data, no p-values on pre-post comparison reported, and small sample size (see Table 7-1). Also, the highly specific patient group is not representative of the range of GERD patients requiring anti-reflux surgery due to the highly specific patient selection criteria [30]. The overall risk of bias was considered moderate because it was unclear if patients entered the study at similar point in the disease, if patients were recruited consecutively, and conclusions concerning effectiveness were not supported by the results (see Appendix Table A-2). Internal validity of the trials conducted was undermined by the use of the concomitant therapy of PPIs in all trials. Occasional or regular use of PPIs was reported to be 12% and 24% in the case series [4, 5], and 27% in the registry [28].

### *Effectiveness data from observational studies*

Large patient groups with non-acute diseases, such as the GERD patient group of this assessment, need the best evidence of controlled trials to prove effectiveness. The lack of RCTs and CTs restricted our analysis to single arm prospective studies as the best available evidence. Consequently, no conclusions on effectiveness of the EST can be made. Nonetheless, the observational data from the prospective trials show a possible effect concerning crucial outcomes. Both case series report improvement in GERD HRQL in on-PPI groups (improvement of 16.5-5 [4] and 9-0 [5]) and in off-PPI groups (improvement of 31-5 [4] and 23.5-0 [5]). The registry study reports slight deterioration by one point [29]. Improvement is also reported in the percentage of days with heartburn and regurgitation in both on-PPI and off-PPI groups and in median DeMeester pH score [7, 18, 29].

Improvement in discontinuation with medication (PPIs) was not reported in the multi-center study [18], but in in the remaining two studies, it was 76% [7] and 73% [29], respectively. The results were heterogeneous with reference to patient satisfaction, which improved from 7-54% in the multi-center study [18] and from 29-100% in the single center study [7]. Esophagitis improved slightly in the multi-center study [18], it was not reported in single centre [7], and insufficiently reported in the registry study [29]<sup>4</sup>.

### *Safety data from observational studies*

With 3-year follow-up data at hand, longer-term data is needed to prove the safety of the EST. Relations between the EST and cardiac issues related either to cardiac devices, or to the EST itself remain to be answered.

**neue Technologie,  
wenige Daten zur  
klinischen Wirksamkeit  
vorhanden: 70 Pts**

**Qualität der Evidenz  
niedrig: nur Fallserien,  
zu kleine Stichproben**

**Moderates Biasrisiko**

**Interne Validität gering**

**Wirksamkeit konnte  
nicht bewertet werden  
auf Grund fehlender  
RCTs,CTs**

**Beobachtungsstudien  
berichten Verbesserung  
in QoL  
sowie**

**in PPI-  
Therapieeinstellungen,  
Patientenzufriedenheit  
und Ösophagitis.**

---

<sup>4</sup> Data reported on 66.6% of pts of which 50% showed improvement by 1 grade, 25% had stable and 25% worsening esophagitis

<p>potentielle Interessenskonflikte nicht angegeben</p>	<p>In both the single center study and the registry study, the chair of the Data Monitoring Committee (DMC) was a consultant for EndoStim Inc. [5, 28] and because these two studies reported on less specific AEs and SAEs than the multi-center study [4], there might be a possibility of underreporting. The background of other committee members were not reported [4] and hence their independence cannot be evaluated.</p>
<p>Pathophysiologie der Erkrankung unklar</p> <p>mehrere Surrogat Parameter zur Quantifizierung von GERD vorhanden</p>	<p><b><i>Mechanisms behind GERD</i></b></p> <p>The mechanisms behind GERD are unclear and only the correct determination of its pathophysiology will help in evaluating the efficacy of anti-reflux treatments [32]. Various surrogate outcomes such as esophageal manometry, 24 pH monitoring, DeMeester score, or LES pressure attempt to quantify GERD. LES residual pressure, the main outcome that the EST claims to improve, was either reported with a statistically insignificant improvement (<math>p=0.8018</math>) [4], or it was not reported in the remaining studies [5, 28]. Other mechanisms possibly having an influence on GERD may have effect on transient LES relaxations, LES compliance, or the acid pocket [5].</p>
<p>Hiatus Hernien Reparatur als potentieller Störfaktor</p>	<p>As hiatal hernias makes acid reflux more likely [15], it is possible that repairing of the hiatal hernia has an impact on the effectiveness of the intervention and hence on GERD symptoms. One study reported on the variable of impact of repairing hiatal hernia <math>\geq 2</math> [4]. Patients with an unrepaired hiatal hernia <math>\geq 2</math> cm or a significant hiatal defect compared to patients with repaired hernia of the same size showed a trend for less improvement in GERD HRQL, percentage of heartburn days and nights, and percentage of regurgitation days and nights [4].</p>
<p>sham RCTs mit PatientInnen relevanten Endpunkten nötig</p>	<p><b><i>Clinical trials</i></b></p> <p>Quality RCTs need to be conducted to prove the EST efficacy. DeMeester suggests that an RCT against PPIs is needed [31], whereas Attwood argues that a comparison between surgical options (EST vs LF) is required as only those patients who are dissatisfied with PPIs will be willing to undergo surgery [32]. It is ambiguous what the appropriate comparator to the EST is. On the one hand, LF is the only established surgical alternative, yet on the other hand, the EST claims to fill the therapeutic gap between patients who are dissatisfied with the PPI treatment and those who are reluctant to undergo LF. The target population of the EST seems to be less severe patients not indicated for fundoplication, which changes the cut-off point of a surgical intervention to the less diseased. In the light of this ambiguity, ethicality of an RCT between the EST and LF is put into question. Hence, under these circumstances, a sham RCT is needed to confirm efficacy of the EST.</p>
<p>Zielpopulation nicht klar definiert</p>	
<p>laufendes sham RCT</p>	<p>Since July 2015, there was an EndoStim Inc. funded sham RCT ongoing in Belgium and France that was terminated due to a suspension of financial support in November 2015 (NCT02514616). Correspondence with EndoStim Inc., however, suggests that the trial was discontinued because a new multi-center trial with a similar design and a larger sample was started. The sites originally participating in NCT02514616 will join the larger FDA approval study (NCT02749071).</p>



**Other technologies**

There are some other emerging technologies aiming to fill the above mentioned therapeutic gap. These can be categorized into 3 groups:

1. radiofrequency ablation of the LES (Stretta System)
2. trans-oral incisionless fundoplication (TIF),  
i.e. suturing of the gastroesophageal junction
3. magnetic sphincter augmentation device (MSAD) [33, 34]

The first two alternatives provide a non-surgical approach, while the MSAD is a laparoscopically implanted ring of magnetic beads made of titanium that is placed around the lower esophagus [33]. Like the EST, MSAD is a reversible procedure with an acceptable safety profile that is lacking robust data on its effectiveness. The TIF seems to be safe and effective with 79-80% response rates, but with disappointing 2-year follow-up results. It is equally recommended only for patients with hiatal hernia <2 cm. The Stretta System is recommended by SAGES for non-complicated GERD and it is the only one that has undergone rigorous evaluation with randomized trials and positive effectiveness results [33, 34].

Untreated chronic reflux might lead to secondary diseases, such as erosive esophagitis, esophageal stricture, Barrett's esophagus, or even esophageal cancer, therefore the effect of EST on these outcomes also needs to be analyzed. In the absence of clear severity scores supporting staging of well-defined indications however, there is a possible issue with the EST that instead of a change in the patient's dietary habits, particularly in the obese, the EST can facilitate unhealthy behaviour. In case the EST fulfils the mentioned therapeutic gap, it can be considered as the first line surgical treatment for prevention of esophageal cancer and, on the long run, as an option bringing savings to the health care system when contrasted to the costly PPI therapy. Moreover, long-term PPI therapy can have serious side-effects, such as decreased calcium absorption, osteoporosis, community acquired pneumonia, Clostridium difficile infection, small intestinal bacterial overgrowth, vitamin B12 deficiency, and drug interactions [35].

Major advantages of the EST known to date are that it is less invasive and reversible, its implantation is associated with a short learning curve for the surgeon, it presumably allows a faster return to normal diet, and it requires a short hospital stay compared to LF. Quality RCTs, in particular a sham RCT, with longer follow-up involving larger number of implanted patients should be conducted in order to prove efficacy of the EST.

**Konkurrierende aufstrebende Technologien: Radiofrequenz Ablation, Trans-orale Inzision der Fundoplicatio, Magnetischer Speiseröhrenring**

**Evidenzlage zu allen Technologien derzeit niedrig**

**in Abwesenheit von klaren GERD Schweregraden: schwierig genaue Indikation für EST zu etablieren könnte ‚ungesundes‘ Verhalten fördern**

**potentiell ökonomische wie gesundheitliche Vorteile durch Wegfall der PPI Medikation,**

**Studien mit größerer Fallzahl nötig**



## 9 Recommendation

In Table 9-1 the scheme for recommendations is displayed and the according choice is highlighted.

Table 9-1: Evidence based recommendations

	The <b>inclusion</b> in the catalogue of benefits is <b>recommended</b> .
	The <b>inclusion</b> in the catalogue of benefits is <b>recommended with restrictions</b> .
X	The inclusion in the catalogue of benefits is <b>currently not recommended</b> .
	The <b>inclusion</b> in the catalogue of benefits is <b>not recommended</b> .

### Reasoning:

The current evidence is not sufficient to prove that the EST is at least equally effective and as safe as the comparator LF. There are no available comparative data on the two procedures or placebo controlled data on the EST and hence, no conclusions are made about the device effectiveness. Concerning safety, only device related complications were reported based upon data from prospective case series. These suggest a relatively safe profile of the EST that, however, needs to be confirmed by a high quality RCT, which will potentially influence the effect estimate considerably.

Currently, there is an ongoing sham-controlled RCT and hence the re-evaluation is recommended in 2022, as December 2021 is its estimated study completion date.

**Evidenz unzureichend;  
derzeit nicht empfohlen**

**1 laufendes RCT,  
Re-Evaluierung 2022**



## 10 References

- [1] SAGES/Society of American Gastrointestinal and Endoscopic Surgeons. Guidelines for Surgical Treatment of Gastroesophageal Reflux Disease (GERD). 2008.
- [2] Rodriguez L, Rodriguez P, Gomez B, Ayala JC, Saba J, Perez-Castilla A, et al. Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. *Surg Endosc*. 2013;27(4):1083-92.
- [3] Bonavina L, Attwood S. Laparoscopic alternatives to fundoplication for gastroesophageal reflux: the role of magnetic augmentation and electrical stimulation of the lower esophageal sphincter. *Dis Esophagus*. 2016;29(8):996-1001.
- [4] Kappelle WFW, Bredenoord AJ, Conchillo JM, Ruurda JP, Bouvy ND, van Berge Henegouwen MI, et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease – interim results of an international multicentre trial. *Aliment Pharmacol Ther*. 2015;42(5):614-25.
- [5] Rodriguez L, Rodriguez P, Gomez B, Ayala JC, Oxenberg D, Perez-Castilla A, et al. Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease. *Surgery*. 2015;157(3):556-67.
- [6] Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology*. 2011;64:383-94.
- [7] Rodriguez L, Rodriguez P, Gomez B, Ayala JC, Oxenberg D, Perez-Castilla A, et al. Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease. *Endoscopy*. 2013;45(8):595-604.
- [8] Rodriguez L, Rodriguez P, Ayala JC, Oxenberg D, Perez-Castilla A, Netto MG. Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES) is successful in treating GERD: One year results. *Surgical Endoscopy and Other Interventional Techniques*. 2013;27((Rodriguez L.; Rodriguez P.; Ayala J.C.; Oxenberg D.; Perez-Castilla A.; Netto M.G.) Surgery, CCO Obesidad Y Diabetes, Clinic Indisa, Gastro Obeso Center, Brazil):S374.
- [9] EndoStim Launches Second Generation Neurostimulation Device for GERD. Dallas: EndoStim Inc.; 2015 [cited 2017 7 February]; Available from: <http://www.endostim.com/636/>.
- [10] EndoStim receives CE Mark for full body MRI use with EndoStim II LES Stimulation System. Dallas: EndoStim Inc.; 2015 [cited 2017 07 February]; Available from: <http://www.endostim.com/endostim-receives-ce-mark-for-full-body-mri-use-with-endostim-ii-les-stimulation-system/>.
- [11] Scott J. EndoStim II Secures CE Mark Approval. Washington st. USA: FDA NEWS; 2015 [cited 2017 February 16]; Available from: <http://www.fdanews.com/articles/171288>.
- [12] SAGES/Society of American Gastrointestinal and Endoscopic Surgeons. Guidelines for Surgical Treatment of Gastroesophageal Reflux Disease (GERD). 2008.
- [13] Jacobsen GR, DuCoin CG. Surgical intervention for the treatment of gastroesophageal reflux disease. *Techniques in Gastrointestinal Endoscopy*. 2015;17(2):70-6.
- [14] Singhal V, Khaitan L. Gastroesophageal Reflux Disease: Diagnosis and Patient Selection. *Indian Journal of Surgery*. 2014;76(6):453-60.
- [15] Kahrilas PJ. Patient information: Acid reflux (gastroesophageal reflux disease) in adults (beyond the basics). In: Talley NJ, editor. *UpToDate*: Wolters Kluwer; 2016.
- [16] Bonavina L. Selected commentary to „esophageal sphincter device for gastroesophageal reflux disease“. *European Surgery – Acta Chirurgica Austriaca*. 2013;45(2):113-6.
- [17] Parekh PJ, Johnson DA. Medical treatment versus surgery for treatment of gastroesophageal reflux disease. *Techniques in Gastrointestinal Endoscopy*. 2015;17(2):53-61.

- [18] Schwaitzberg S. Surgical management of gastroesophageal reflux in adults. In: Friedberg JS, Talley NJ, editors.: UpToDate; 2014.
- [19] Nieponice A, Borbely Y, Rodriguez L, Schulz HG, Ortiz C, Talbot M, et al. Endostim® les stimulation therapy improves gerd in patients with laparoscopic sleeve gastrectomy (LSG). *Surgical Endoscopy and Other Interventional Techniques*. 2016;30(Nieponice A.) Fundacion Favaloro, Argentina):S263.
- [20] Liakakos T, Karamanolis G, Patapis P, Misiakos E. Gastroesophageal Reflux Disease: Medical or Surgical Treatment? *Gastroenterology Research and Practice*. 2009. Epub Gastroenterology Research and Practice.
- [21] Liu JJ, Saltzman JR. Refractory gastro-oesophageal reflux disease: diagnosis and management. *Drugs*. 2009;69(14):1935-44.
- [22] Kahrilas PJ. Patient information: Acid reflux (gastroesophageal reflux disease) in adults (beyond the basics). Talley NJ, editor: Wolters Kluwer; 2016.
- [23] Varannes SB, Löfman HG, Karlsson M, Wahlqvist P, Ruth M, Furstnau ML, et al. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. *BMC Gastroenterology*. 2013;13(39).
- [24] Koop H, Fuchs KH, Labenz J, Jansen L, Messmann H, Miehke S, et al. Gastroösophageale Refluxkrankheit unter Federführung Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)2014.
- [25] Katz P, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2013;108:308-28. Epub 19 February 2013.
- [26] Neuhauser B, Bonatti H, Hinder RA. Treatment strategies for gastroesophageal reflux disease. *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen*. 2003;74(7):617-24, discussion 24-25.
- [27] Schwaitzberg S. Surgical management of gastroesophageal reflux in adults. Friedberg JS, Talley NJ, editors2014.
- [28] Rodriguez L, Rodriguez PA, Gomez B, Netto MG, Crowell MD, Soffer E. Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: long-term 3-year results. *Surg Endosc*. 2016;30(7):2666-72.
- [29] Rinsma NF, Bouvy ND, Masclee AAM, Conchillo JM. Electrical stimulation therapy for gastroesophageal reflux disease. *J Neurogastroenterol Motil*. 2014;20(3):287-93.
- [30] Attwood SE. Electrical stimulation for gastroesophageal reflux disease: formal randomized clinical trials are needed. *Surgery*. 2015;157(3):568-9.
- [31] DeMeester TR. Regarding „Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease“. *Surgery*. 2015;158(5):1448.
- [32] Attwood S. Reply „Electrical stimulation for GERD: The need for controlled clinical trials“. *Surgery*. 2015;158(5):1449.
- [33] Bonavina L, DeMeester T, Fockens P, Dunn D, Saino G, Bona D, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. *Annals of Surgery*. 2010;252(5):857-62.
- [34] Liu JJ, Saltzman JR. Refractory gastro-oesophageal reflux disease: diagnosis and management. *Drugs*. 2009;69(14):1935-44.
- [35] Chiu J, E. S. Novel surgical options for gastroesophageal reflux disease. *Expert Review of Gastroenterology and Hepatology*. 2015;9(7):943-51.
- [36] ClinicalTrials.gov. Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD. *ClinicalTrials.gov*; 2017 [cited 2017 21 February]; Available from: <https://clinicaltrials.gov/ct2/show/NCT01574339>.
- [37] EUnetHTA Joint Action 2 WP. Levels of evidence: Internal validity (of randomized controlled trials). 2013.
- [38] EUnetHTA Joint Action 2. Internal validity of non-randomised studies (NRS) on interventions. 2015.

# Appendix

## Evidence tables of individual studies included for clinical effectiveness and safety

Table A-1: EST: Results from observational studies

	Kappelle [4, 36] (2015)	Rodriguez [5] (2015)	Rodriguez [28] (2016)
Country	Chile, Colombia, India, Netherlands, Mexico, New Zealand, United Kingdom <sup>5</sup>	Chile	
Sponsor	EndoStim Inc.		EndoStim Inc.
Study design	Multi-centre, prospective, international, open-label case series (NCT01574339)	Single-centre, prospective, open-label case series (NCT01578642)	Single-centre, prospective registry (NCT02441400)
Intervention (I)	Electric stimulation therapy (EndoStim <sup>®</sup> LES Stimulator)		
Comparator (C)	none		
Number of pts (I vs. C)	44 <sup>6</sup>	26 <sup>7</sup>	18 <sup>8</sup>
Inclusion criteria	Pts 21-80yrs, reflux symptoms, GERD-HRQL score $\geq 20$ off PPIs & an increase of $\geq 5$ on PPIs, prior PPI use for 12 mos, diagnosis based on 24-h pH monitoring result, LES end-expiratory 5-15 mmHg, peristaltic contractions in $\geq 50\%$ of swallows with contraction amplitude of $\geq 30$ mmHg oesophageal manometry, excessive lower esophageal acid exposure as pH $< 4.0$ for $\geq 5\%$ of the total time.	Pts 21-65yrs, reflux symptoms $\geq 6$ mos, prior PPI use, GERD-HRQL score $\geq 20$ off PPIs & an increase of $\geq 10$ on PPIs, ASA Physical Status Classification $\leq 11$ , distal esophageal acid exposure during 24-hour pH measurement pH of $\leq 4$ for $> 5\%$ of total or $> 3\%$ of supine, time off, anti-secretory therapy, LES end-expiratory $\geq 5$ mmHg, esophageal body contraction amplitude of $\geq 30$ mmHg for $\geq 70\%$ of swallows and $\geq 50\%$ peristaltic contractions on manometry, esophagitis grade $\leq C$ .	NA
Exclusion criteria	History of esophageal or gastric surgery, gastroparesis, multi-system disease, autoimmune or connective tissue disorder in past 2 yrs, Barrett's epithelium, any grade dysplasia, hiatal hernia $> 3$ cm, esophagitis grade D on upper endoscopy within 6 mos, BMI $> 35$ , T1DM or uncontrolled T2DM defined as HbA1c $\geq 9.5$ in the previous 6ms, or T2DM for $\geq 10$ years, suspected or confirmed esophageal or gastric cancer, any malignancy in last 2 yrs, esophageal or gastric varices or dysphagia or oesophageal peptic stricture, significant cardiac arrhythmia or cardiovascular disease, implanted electrical stimulator or chronic anticoagulant therapy, pregnant pts.	Non-GERD esophageal motility disorders or gastroparesis, multi-system diseases, Barrett's ( $> M2; > C1$ ) esophagus, any grade of dysplasia, hiatal hernia $\geq 3$ cm, BMI $> 35$ , uncontrolled type 2 or history of type 2 or 1 diabetes mellitus for $> 10$ yrs, esophageal or gastric malignancy or varices, cardiac arrhythmia, ectopy, significant cardiovascular disease, implanted electro-medical device, pregnancy, esophageal or gastric surgery, anti-reflux surgery.	NA

<sup>5</sup> While the study refers to 8 countries and 10 sites, [www.clinicaltrials.gov](http://www.clinicaltrials.gov) lists 7 countries and 9 sites.

<sup>6</sup> Baseline characteristics on 42pts

<sup>7</sup> 25 received intervention

<sup>8</sup> Baseline characteristics on 15pts

	Kappelle [4, 36] (2015)	Rodriguez [5] (2015)	Rodriguez [28] (2016)
Primary outcome measure			
Baseline patient characteristics (I vs. C)			
Mean age, yrs (SD)	49.6 (12.4)	52 (12)	56.1 (9.7)
Sex, female vs. male	18 vs. 24	11 vs. 14	7 vs. 8
Mean BMI, (SD)	27.2 (2.4)	27.7 (3.2)	27.4 (3.2)
* Hiatal hernia	39/22/39	88/8/4	93.3/0/6.7
* none/<2 cm/>2 cm, %			
* Mean yrs of PPI use (SD)	NA	5.6 (3.4)	5.9 (3.3)
* Mean yrs with GERD (SD)	NA	11.0 (7.9)	12.2 (9.1)
Follow-up time, yrs	0.5	2	3
Loss to follow-up, %	6.8 <sup>9</sup>	19.2 <sup>10</sup>	16.6 <sup>11</sup>
<b>Outcomes</b>			
<b>Efficacy</b>			
Improvement in median GERD HRQL score (pre-op./last follow-up) <sup>12</sup> (IQR)			
* on-PPI	16.5 (9.0–22.8)/5.0 (3.0–9.0) <sup>13</sup>	9 (6–10)/0 (0–3) <sup>14</sup> /1 (0–2)	
* off-PPI	31.0 (26.2–36.8)/5.0 (3.0–9.0)	23.5 (21–25.3)/0 (0–3)/1 (0–2)	
Median heartburn % of days (pre-op./last follow-up) (IQR)			
* days	86 (64–100)/17 (0–93) <sup>15</sup>	92/7 <sup>16</sup> /NA	
* nights	64 (43–86)/0 (0–8)	71/0/NA	

<sup>9</sup> 1 loss to follow-up, 1 Toupet fundoplication due to hiatal hernia >3 cm, 1 trocar perforation of the intestine during implant procedure

<sup>10</sup> 1 loss to follow-up, 1 implant not attempted due to hiatal hernia >3 cm, 3 voluntary withdrawals

<sup>11</sup> of the 21pts at 2 yr follow-up, 3 did not join 5 year observational registry, 3 losses to follow-up

<sup>12</sup> The total GERD-HRQL score represents a summation of 10 items (questions about heartburn, difficulty swallowing, bloating, satisfaction and medication take). The best possible score is 0 (i.e., asymptomatic in each item), and the worst possible scores is 50 (incapacitated in each item)

<sup>13</sup> 42 pts at baseline, 41 at last follow-up

<sup>14</sup> 24 pts at baseline, 21 at last follow-up

<sup>15</sup> 35 pts at baseline, 34 pts at last follow-up

<sup>16</sup> 18 pts' analysis



	Kappelle [4, 36] (2015)	Rodriguez [5] (2015)	Rodriguez [28] (2016)
Median regurgitation % of days (pre-op./last follow-up) (IQR) * days * nights	79 (54–100)/0 (0–21) <sup>17</sup> 50 (15–79)/0 (0–7)	66/0 <sup>18</sup> /NA 31/0/NA	
Discontinuation with medication (PPIs), % at last follow-up	NA	76/73	
Median DeMeester pH score <sup>19</sup> (pre-op./last follow-up) (IQR)	35.1 (27.1–51.9)/17.5 (10.9–23.4) <sup>20</sup>	36.6 (29.6–50.2)/16.1 12.2–29.1 <sup>21</sup> /12.8 (7.2–18.8)	
Patient satisfaction while on PPIs at baseline, % (pre-op./last follow-up)	7/54 <sup>22</sup>	29/100/NA	
Esophagitis, % (pre-op./last follow-up) * None * Grade A * Grade B * Grade C	41/51 <sup>23</sup> 31/31 23/18 5/0	NA/NA NA/NA NA/NA NA/NA	0/NA <sup>24</sup> 60/NA 33.3/NA 6.7/NA
<b>Safety</b>			
Total number of AE	110 (in 32pts)	65 (in 19pts)	NA
Of which SAE	3 (2%)	2 (3%)	
AE related	52		
AE non-related	56		

<sup>17</sup> 35 pts at baseline, 34 pts at last follow-up

<sup>18</sup> 18 pts' analysis

<sup>19</sup> Global measure of esophageal acid exposure that quantifies gastroesophageal reflux. A DeMeester score > 14.72 indicates reflux.

<sup>20</sup> 42 pts at baseline, 40 at last follow-up

<sup>21</sup> 24 pts at baseline, 18 at last follow-up

<sup>22</sup> 42 pts at baseline, 39 at last follow-up

<sup>23</sup> out of 39 pts

<sup>24</sup> data on 12pts: 6pts showed improvement by 1 grade, 3pts has stable and 3pts worsening esophagitis

	Kappelle [4, 36] (2015)	Rodriguez [5] (2015)	Rodriguez [28] (2016)
Device/procedure-related mild AEs noted during the study, % of pts			
Post-operative bloating/belching	7.1	0	0
Constipation	2.4	NA	NA
Post-operative dysphagia	9.5	0	0
Epigastric pain	2.4	NA	NA
Hiccups	4.8	NA	NA
Nausea/vomiting	7.1	12	0
Inability to vomit	4.8	NA	NA
Weight loss/anorexia	11.9	NA	NA
Fever	2.4	NA	NA
Pain/discomfort	45.2	20	0
Impedance out of range	4.8	NA	NA
Mesh repair hernia cicatricialis	2.4	NA	NA
Skin infection at pocket site	NA	4	0
Psychotic disturbance/nervous breakdown	NA	4	0
Shoulder pain and a hypersensitive episode	NA	8	0
Device/procedure-related SAEs			
Intraoperative complications in % of pts			
* Trocar perforation of the small bowel during laparoscopy	2.4	NA	NA
Postoperative complications in % of pts			
* Device related complications (Lead erosion through esophagus, explantation)	2.4	NA	NA
* Reoperation rate	NA	NA	NA
* Hospital readmission	NA	NA	NA

MSAD – Magnetic Sphincter Augmentation Device, LP – Laparoscopic, LF – Laparoscopic Fundoplication, PPI – Proton Pump Inhibitor; Pts – patients;  
GERD HRQL – Gastroesophageal Reflux Disease Health-Related Quality of Life, BMI – Body Mass Index, yrs – year; mos – months; min – minutes; pre-op. – pre-operative;  
AEs – adverse events; SAEs – serious adverse events; NA – data not available

## Risk of bias tables

Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA [37] and in the Guidelines of EUnetHTA [38].

Table A-2: Risk of bias – study level

Study reference/ID	Prospective case series		Prospective registry
	Kappelle [4, 36], 2015	Rodriguez [5], 2015	Rodriguez [28], 2016
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section?	Yes	Yes	Yes
2. Are the characteristics of the participants included in the study described?	Yes	Yes	Yes
3. Were the cases collected in more than one centre?	Yes	No	No
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate?	Yes	Yes	Yes
5. Were participants recruited consecutively?	Unclear <sup>25</sup>	Unclear <sup>26</sup>	Unclear <sup>27</sup>
6. Did participants enter the study at similar point in the disease?	Unclear	Unclear <sup>28</sup>	Unclear
7. Was the intervention clearly described in the study?	Yes	Yes	Yes
8. Were additional interventions (co-interventions) clearly reported in the study?	Yes	Yes	Yes
9. Are the outcome measures clearly defined in the introduction or methods section?	Yes	Yes	Yes
10. Were relevant outcomes appropriately measured with objective and/or subjective methods?	Yes	Yes	Yes
11. Were outcomes measured before and after intervention?	Yes	Yes	Yes
12. Were the statistical tests used to assess the relevant outcomes appropriate?	Yes	Yes	Yes
13. Was the length of follow-up reported?	Yes	Yes	Yes
14. Was the loss to follow-up reported?	Yes	Yes	Yes
15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes?	Yes	Partially reported	Yes
16. Are adverse events reported?	Yes	Yes	Yes
17. Are the conclusions of the study supported by results?	Partially reported	Partially reported	Partially reported
18. Are both competing interest and source of support for the study reported?	Yes	Yes	Yes
	Moderate	Moderate	Moderate

<sup>25</sup> “Unclear”: 110pts screened and 66 specified screen failures

<sup>26</sup> “Unclear”: 75pts screened and 49 unspecified screen failures

<sup>27</sup> “Unclear”: 21pts at 24mos follow-up, 18 recruited for 5 yr registry (3/21 elected not to join the 5 year observational registry)

<sup>28</sup> “Unclear”: only mean duration of PPI use and mean duration of GERD symptoms is reported.

## Applicability table

Table A-3: Summary table characterising the applicability of a body of studies

Domain	Description of applicability of evidence
<b>Population</b>	Study population represents a narrow spectrum of GERD patients as predefined by the manufacturer and hence for the most part, the target population does not differ from the enrolled population. The inclusion criteria predominantly do not reflect severe refractory GERD with hiatal hernias >3 cm, motility disorders, Barrett's esophagus or grade D esophagitis, but only mild to moderate GERD with incomplete symptom control by PPIs.
<b>Intervention</b>	Electric stimulation therapy device (EST) inserted through laparoscopic surgery. Product name: EndoStim® LES Stimulator
<b>Comparators</b>	Standard surgical treatment of GERD and Nissen fundoplication and partial, or Toupet fundoplication. However, there is a slight ambiguity as EST attempts to place itself into the „treatment gap“ for which there is no comparator. It aims at patients who have persistent GERD, incomplete symptom control by PPIs, but whose condition is not severe enough to undergo any type of non-reversible fundoplication.
<b>Outcomes</b>	Effectiveness outcomes reported in the registry study are GERD HRQL, heartburn, regurgitation, discontinuation with PPI medication, DeMeester score, patient satisfaction, and esophagitis. Follow-up time was 0.5 to 3 yrs. The outcomes measured present the most important benefits. Safety outcomes that are most frequently reported in the three studies considered are post-operative bloating/belching, post-operative dysphagia, nausea/vomiting, pain/discomfort, device and procedure related side effects. Follow-up time ranged from 0.5 to 3 yrs and hence short-term safety profile of the EST on GERD may be assessed even though its comparative safety to LF cannot. The outcomes measured do present the most important health threats associated with the EST.
<b>Setting</b>	All of the studies included were either single-centre or multi-centre studies, with clinical centres based in Europe, South and Central America, Asia, New Zealand, and the United States. Clinical settings were not described in all of the studies, but it is likely that all patients received standard care at university hospitals or transplant centres. Thus, it can be assumed that the results reflect a wide spectrum of clinical routines with regard to patient selection and treatment modalities and, therefore, the results are transferable to the Austrian setting. The surgeon's technical expertise likely determines the risk of local side effects. If introduced as a new treatment method in European hospitals, the treatment with EST will certainly be accompanied by a learning curve.

## List of ongoing trials

Table A-4: List of ongoing trials of the EST

Identifier/ Trial name	Patient population	Intervention	Comparison	Primary Outcome	Primary completion date	Sponsor
NCT02441400 EndoStim Patient Registry (RESTORE)	Patients with GERD	EndoStim® LES Stimulator	Single arm, no comaprison group	Assessment of safety by incidence and severity of adverse events through 60-month (5 years) follow-up.	May 2019	EndoStim Inc.
LESS GERD Registry	Patients with GERD	EndoStim® LES Stimulator	Single arm, no comaprison group	NA	NA	EndoStim Inc.
NCT02749071 <sup>29</sup> An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux	Patients with GERD	EndoStim® LES Stimulator	Sham	Rate of (occurence) device and/or procedure- related serious adverse events in 12mos Percentage of subjects achieving pH success (pH<4 for mo more than 5,3% of time or at least 50% improvement in pH compared to baseline)	June 2017	EndoStim Inc.
NCT02514616 Electrical Stimulation Therapy (EST) of the Lower Esophageal Sphincter (GERD) (EST-SHAM-EUR)	Patients with GERD	EndoStim® LES Stimulator	Sham	Efficacy of EST on GERD symptoms (mean improvement in the GERD- health-related quality of life (HRQL) scores from baseline in control and treatment groups) at 14 weeks follow-up	November 2015	EndoStim Inc.
NCT02210975 An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy	Patients with GERD after Sleeve Gastrectomy	EndoStim® LES Stimulator	No comparitor	The incidence and severity of any complications that are associated with the investigational stimulation device throughout the follow-up period at 12 month follow-up Disease specific quality of life at 6 and 12 month follow-up	January 2016	EndoStim Inc.

<sup>29</sup> Terminated to become part of a larger trial NCT02749071

## Literature search strategies

### Search strategy for Cochrane

Search Name: Electrostimulation for GERD	
Search Date: 02/01/2017 18:03:53.310	
Description: (MEL2017 MS/KR)	
ID	Search
#1	MeSH descriptor: [Gastroesophageal Reflux] explode all trees
#2	„gastro*esophageal reflux“ (Word variations have been searched)
#3	„gastro-esophageal reflux“ (Word variations have been searched)
#4	GER:ti,ab,kw (Word variations have been searched)
#5	GERD:ti,ab,kw (Word variations have been searched)
#6	GORD:ti,ab,kw (Word variations have been searched)
#7	#1 OR #2 OR #3 OR #4 OR #5 OR #6
#8	MeSH descriptor: [Electric Stimulation Therapy] explode all trees
#9	Electric* near Stimul*:ti,ab,kw (Word variations have been searched)
#10	MeSH descriptor: [Electric Stimulation] explode all trees
#11	electrostimul*:ti,ab,kw (Word variations have been searched)
#12	electro-stimul*:ti,ab,kw (Word variations have been searched)
#13	EST:ti,ab,kw (Word variations have been searched)
#14	EndoStim:ti,ab,kw (Word variations have been searched)
#15	LES near Stimul*:ti,ab,kw (Word variations have been searched)
#16	#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#17	#7 AND #16
Total: 23 Hits	

### Search strategy for CRD

Search Name: Electrotherapy for GERD (MEL2017 MH/KR)	
Search Date: 02/01/2017	
ID	Search
#1	MeSH DESCRIPTOR Gastroesophageal Reflux EXPLODE ALL TREES
#2	(gastro*esophageal reflux)
#3	(gastro-esophageal reflux)
#4	(gastro-oesophageal reflux)
#5	(GER)
#6	(GERD)
#7	(GORD)
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9	MeSH DESCRIPTOR Electric Stimulation Therapy EXPLODE ALL TREES
#10	(Electric* NEAR Stimul*)
#11	MeSH DESCRIPTOR Electric Stimulation EXPLODE ALL TREES
#12	(electrostimul*)
#13	(electro-stimul*)
#14	(EST)
#15	(EndoStim)
#16	(LES NEAR Stimul*)
#17	#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
#18	#8 AND #17
Total: 2 Hits	

## Search strategy for Embase

Search Name: Electrostimulation for GERD	
Search Date: 02/01/2017	
ID	Search
#23	'gastroesophageal reflux'/exp OR 'gastroesophageal reflux':ab,ti OR 'gastrooesophageal reflux':ab,ti OR 'gastro-esophageal reflux':ab,ti OR 'gastro-oesophageal reflux':ab,ti OR ger:ab,ti OR gerd:ab,ti OR gord:ab,ti AND ('electrotherapy'/mj OR (electric* NEAR/5 stimul*):ti,ab OR 'electrostimulation'/exp OR lectrostimul*:ti,ab OR 'electro stimul*':ti,ab OR est:ti,ab OR endostim:dn OR endostim*:ti,ab OR les:dn OR (les NEAR/1 stimul*):ti,ab)
Total: 264 Hits	

## Search strategy for Medline

Search Name: Electrostimulation for GERD	
Search Date: 02/01/2017	
ID	Search
#1	1 exp Gastroesophageal Reflux/(26275)
#2	2 gastro?esophageal reflux.mp. (31464)
#3	3 gastro-?esophageal reflux.mp. (1502)
#4	4 GER.mp. (3394)
#5	5 GERD.mp. (7461)
#6	6 GORD.mp. (788)
#7	7 1 or 2 or 3 or 4 or 5 or 6 (34515)
#8	8 exp Electric Stimulation Therapy/(74443)
#9	9 (Electric* adj5 Stimul*).mp. (168133)
#10	10 exp Electric Stimulation/(132669)
#11	11 (therap* or treatment* or program*).mp. (6907194)
#12	12 10 and 11 (16907)
#13	13 electrostimul*.mp. (3382)
#14	14 electro-stimul*.mp. (309)
#15	15 EST.ti,ab. (11102)
#16	16 EndoStim.mp. (11)
#17	17 LES Stimul*.mp. (76)
#18	18 8 or 9 or 12 or 13 or 14 or 15 or 16 or 17 (230916)
#19	19 7 and 18 (150)
#20	20 remove duplicates from 19 (128)
Total: 128 Hits	

## Search strategy for PubMed

Search Name: MELs 2017: Electric Stimulation Therapy for patients with GERD	
Search Date: 03/02/2017	
ID	Search
#1	((„Gastroesophageal Reflux“[Mesh] OR „gastroesophageal reflux“ OR „gastrooesophageal reflux“ OR „gastro-esophageal reflux“ OR „gastro-oesophageal reflux“ OR GER OR GERD OR GORD)) AND (Electric Stimulation Therapy OR (Electric Stimulation AND (therap* OR treatment* OR program* OR procedure* OR intervention* OR technolog*)) OR electrostimul* OR electro-stimul* OR EST[tiab] OR EndoStim OR „LES Stimulator“)
Total: 99 Hits	



Ludwig Boltzmann Institut  
Health Technology Assessment